Star Equity (STRR) 10-K 6 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Feb. 24, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Entity Registrant Name	DIGIRAD CORP
Entity Central Index Key	707388
Current Fiscal Year End Date	-19
Entity Filer Category	Non-accelerated Filer
Document Type	10-K
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		18,630,945
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$58,692,296

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Diagnostic Services	$42,170	$37,171	$36,064
Diagnostic Imaging	13,438	12,205	14,449
Total revenues	55,608	49,376	50,513
Cost of revenues:
Diagnostic Services	31,721	27,828	27,293
Diagnostic Imaging	7,247	7,432	10,128
Total cost of revenues	38,968	35,260	37,421
Gross profit	16,640	14,116	13,092
Operating expenses:
Research and development	0	1,025	3,716
Marketing and sales	4,730	4,411	6,402
General and administrative	8,344	8,118	7,839
Amortization of intangible assets	356	231	233
Restructuring charges	692	1,728	0
Gain on sale of assets and license agreement	0	-1,568	0
Total operating expenses	14,122	13,945	18,190
Income (loss) from operations	2,518	171	-5,098
Other income (expense):
Interest and other income, net	58	63	101
Interest expense	-39	-15	-4
Total other income	19	48	97
Income (loss) before income taxes	2,537	219	-5,001
Income tax benefit (expense)	-62	45	77
Net income (loss)	2,475	264	-4,924
Net income (loss) per share:
Earnings Per Share, Basic (in dollars per share)	$0.13	$0.01	($0.26)
Earnings Per Share, Diluted (in dollars per share)	$0.13	$0.01	($0.26)
Shares used in per share computations:
Weighted average shares outstanding - basic (in dollars per share)	18,571	18,789	19,274
Weighted average shares outstanding - diluted (in dollars per share)	18,878	19,159	19,274
Common stock dividends declared (usd per share)	$0.20	$0.05	$0
Other Comprehensive loss:
Unrealized loss on marketable securities	-17	-19	-16
Total other comprehensive loss	-17	-19	-16
Comprehensive loss	2,458	245	-4,940
Accumulated Other Comprehensive Income (Loss) [Member]
Other Comprehensive loss:
Unrealized loss on marketable securities	($17)	($19)	($16)

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$14,051	$18,744
Securities available-for-sale	7,935	7,673
Accounts receivable, net	5,989	5,430
Inventories, net	3,644	3,881
Other current assets	856	697
Restricted cash	477	244
Total current assets	32,952	36,669
Property and equipment, net	4,766	4,153
Property and equipment, net	2,577	353
Goodwill	1,337	184
Other assets	269	92
Total assets	41,901	41,451
Liabilities and stockholders' equity
Accounts payable	1,423	611
Accrued compensation	3,261	3,472
Accrued warranty	176	137
Deferred revenue	1,644	1,631
Other current liabilities	1,789	1,774
Total current liabilities	8,293	7,625
Other liabilities	963	440
Total liabilities	9,256	8,065
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.0001 par value: 80,000,000 shares authorized; 18,615,945 and 18,504,279 shares issued and outstanding (net of treasury shares) at December 31, 2014 and 2013, respectively	2	2
Treasury stock, at cost; 2,588,484 shares at December 31, 2014 and 2013	-5,728	-5,728
Additional paid-in capital	153,769	156,968
Accumulated other comprehensive loss	-19	-2
Accumulated deficit	-115,379	-117,854
Total stockholders’ equity	32,645	33,386
Total liabilities and stockholders’ equity	$41,901	$41,451

Consolidated_Balance_Sheet_Par

Consolidated Balance Sheet Parentheticals (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred Stock, Par value (usd per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock, Par value (usd per share)	$0.00	$0.00
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	18,615,945	18,504,279
Common Stock, shares outstanding	18,615,945	18,504,279
Treasury stock, shares	2,588,484	2,588,484

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating activities
Net income (loss)	$2,475	$264	($4,924)
Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities:
Depreciation	1,579	1,682	1,898
Amortization of intangible assets	356	231	233
Provision for bad debts	311	-150	-30
Stock-based compensation	326	340	630
Gain on sale of assets and license agreement	-77	-1,621	-104
Amortization of premium on investments	198	192	140
Changes in operating assets and liabilities:
Accounts receivable	-614	1,049	21
Inventories	300	1,136	1,057
Other assets	-302	-86	127
Accounts payable	776	-935	216
Accrued compensation	-380	1,108	73
Deferred revenue	13	-218	-250
Other liabilities	-448	-791	-119
Restricted cash	-233	0	-50
Net cash provided by (used in) operating activities	4,280	2,201	-1,082
Investing activities
Purchases of property and equipment	-1,258	-726	-936
Net proceeds from sale of assets and license agreement	103	1,697	118
Net cash paid for acquisition	-3,447	0	-475
Purchases of securities available-for-sale	-2,617	-4,679	-4,887
Sales and maturities of securities available-for-sale	2,140	4,474	3,465
Net cash provided by (used in) investing activities	-5,079	766	-2,715
Financing activities
Issuances of common stock	188	919	300
Repurchases of common stock	0	-3,642	-1,028
Dividends paid	-3,713	-925	0
Repayments of Long-term Debt	-131	0	0
Repayment of obligations under capital leases	-238	-89	0
Net cash used in financing activities	-3,894	-3,737	-728
Net increase in cash and cash equivalents	-4,693	-770	-4,525
Cash and cash equivalents at beginning of year	18,744	19,514	24,039
Cash and cash equivalents at beginning of year	14,051	18,744	19,514
Non-Cash Investing Activities
Assets acquired by entering into capital lease	521	490	83
Leasehold improvements paid for by lessor	$212	$0	$0

Consolidated_Statements_Of_Sto

Consolidated Statements Of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
In Thousands, except Share data, unless otherwise specified
Balance at Dec. 31, 2011	$41,487	$2	($1,058)	$155,704	$33	($113,194)
Balance (shares) at Dec. 31, 2011		18,901,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	630			630
Shares issued under stock incentive plans (shares)		734,000
Shares issued under stock incentive plans	300			300
Repurchases of common stock (shares)		-491,000
Repurchases of common stock	-1,028		-1,028
Net income (loss)	-4,924					-4,924
Unrealized loss on securities available-for-sale	-16				-16
Balance at Dec. 31, 2012	36,449	2	-2,086	156,634	17	-118,118
Balance (shares) at Dec. 31, 2012		19,144,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	340			340
Shares issued under stock incentive plans (shares)		875,000
Shares issued under stock incentive plans	919			919
Repurchases of common stock (shares)		-1,515,000
Repurchases of common stock	-3,642		-3,642
Dividends paid	-925			-925
Net income (loss)	264					264
Unrealized loss on securities available-for-sale	-19				-19
Balance at Dec. 31, 2013	33,386	2	-5,728	156,968	-2	-117,854
Balance (shares) at Dec. 31, 2013	18,504,279	18,504,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	326			326
Shares issued under stock incentive plans (shares)		112,000
Shares issued under stock incentive plans	188			188
Dividends paid	-3,713			-3,713
Net income (loss)	2,475					2,475
Unrealized loss on securities available-for-sale	-17				-17
Balance at Dec. 31, 2014	$32,645	$2	($5,728)	$153,769	($19)	($115,379)
Balance (shares) at Dec. 31, 2014	18,615,945	18,616,000

The_Company_Notes

The Company (Notes)	12 Months Ended
	Dec. 31, 2014
The Company [Abstract]
The Company	The Company
	Digirad Corporation (Digirad), a Delaware corporation, is one of the largest national providers of in-office nuclear cardiology imaging and ultrasound imaging services, and also provides cardiac event monitoring services. These services are provided to physician practices, hospitals, and imaging centers through our Diagnostic Services reportable segment. Digirad also sells medical diagnostic imaging systems, including solid-state gamma cameras, for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products sold, through our Diagnostic Imaging reportable segment. These two reportable segments, Diagnostic Services and Diagnostic Imaging, are collectively referred to herein as the “Company.”
	The accompanying consolidated financial statements include the operations of both segments. Intercompany accounts and transactions are accounted for at cost and have been eliminated in consolidation. All our long-lived assets are located in the United States and substantially all of our revenues arise from sales activity in the United States.

Basis_Of_Presentation_And_Sign

Basis Of Presentation And Significant Accounting Policies (Notes)	12 Months Ended
	Dec. 31, 2014
Basis of Presentation and Significant Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies
	Basis of Presentation
	The consolidated financial statements are prepared in conformity with United States generally accepted accounting principles (GAAP) and include the financial statements of the Company and its wholly owned subsidiaries. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates. All significant intercompany accounts and transactions have been eliminated.
	The financial results for the year ended December 31, 2014 include the financial results of Telerhythmics, LLC for the period since the acquisition date of March 13, 2014. See Note 3 to the audited consolidated financial statements for more information related to the acquisition of Telerhythmics, LLC.
	Revenue Recognition
	We derive revenues primarily from providing in-office services related to the performance of cardiac diagnostic imaging procedures, cardiac event monitoring, and from selling and servicing solid-state digital gamma cameras. We recognize revenue in accordance with the authoritative guidance for revenue recognition, when all of the following four criteria are met: (i) a contract or sales arrangement exists; (ii) products have been shipped and title has transferred or services have been rendered; (iii) the price of the products or services is fixed or determinable; and (iv) collectability is reasonably assured. The timing of revenue recognition is based upon factors such as passage of title and risk of loss, the need for installation, and customer acceptance. These factors are based on the specific terms of each contract or sales arrangement.
	Diagnostic Services imaging services revenue is derived from our ability to provide our physician customers with our services, which includes use of our imaging system, qualified personnel, and related items required to perform imaging in their own offices and bill Medicare, Medicaid, and other payors for in-office nuclear and ultrasound diagnostic imaging procedures. Revenue related to Diagnostic Imaging services is recognized at the time services are performed and collection is reasonably assured. Diagnostic Services imaging services are generally billed on a per-day basis under annual contracts for nuclear diagnostic imaging, which specify the number of days of service to be provided, or on a flat rate month-to-month basis for ultrasound imaging.
	Our cardiac event monitoring services are provided primarily through an independent diagnostic testing facility model which allows us to bill Medicare, Medicaid, or one of the third-party healthcare insurers directly for services provided. We also receive reimbursement directly from patients through co-pays and self-pay arrangements. Billings for services reimbursed by third-party payors, including Medicare, are recorded as revenue net of contractual allowances. Contractual allowances are estimated based on historical collections by Current Procedural Terminology (CPT) code for specific payors, or class of payors. Adjustments to the estimated receipts, based on final settlement with the third party payors, are recorded upon settlement.
	Diagnostic Imaging product revenues are generated from the sales of gamma cameras and follow-on maintenance service contracts. We generally recognize revenue upon delivery and acceptance by customers. We also provide installation and training for camera sales in the United States. Installation and initial training is generally performed shortly after delivery and represents a cost which we accrue at the time revenue is recognized. Neither service is essential to the functionality of the product. Maintenance services are sold beyond the term of the warranty, which is generally one year from the date of purchase. Revenue from these contracts is deferred and recognized ratably over the period of the obligation and is included in Diagnostic Imaging sales.
	Multiple Element Arrangements
	In fiscal year 2013, we sold all of our assets specifically related to an uncommercialized surgical imaging system previously in development, as well as licensed certain existing Company technology. The transaction was accounted for in accordance with the authoritative guidance for multiple element arrangements. We identified the deliverables at the inception of the agreement and determined which items had value to the customer on a standalone basis, and were therefore separate units of accounting. Non-contingent arrangement consideration was allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each unit of accounting was determined using best estimate of selling price, because neither vendor specific objective evidence (VSOE) of selling price nor third-party evidence of selling price existed for the units of accounting. The non-contingent amount of arrangement consideration allocated to each unit of account was recognized upon performance and delivery of the related unit of accounting.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes to the consolidated financial statements. Significant estimates and judgments include those related to revenue recognition, multiple element arrangements, reserves for doubtful accounts and contractual allowances, and inventory valuation. Actual results could differ from those estimates.
	Concentration of Credit Risk and Significant Customers
	Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents, short-term investments, and accounts receivable. We limit our exposure to credit loss by placing our cash and investments in high credit quality financial institutions and investment grade corporate debt securities. Additionally, we have established guidelines regarding diversification of our investments and their maturities, which are designed to maintain principal and maximize liquidity. For 2014, Emory Healthcare represented 10.9% of our consolidated revenues and 14.3% of our Diagnostic Services revenues. Prior to 2014, no single customer exceeded 10% of our consolidated revenues. We believe we have good relations with Emory Healthcare, however, if we were to lose Emory Healthcare as a customer, it would likely have a material adverse affect on our operations.
	Fair Value of Financial Instruments
	The authoritative guidance for fair value measurements defines fair value for accounting purposes, establishes a framework for measuring fair value, and provides disclosure requirements regarding fair value measurements. The guidance defines fair value as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. The degree of judgment utilized in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Our financial instruments primarily consist of cash equivalents, securities available-for-sale, accounts receivable, other current assets, restricted cash, accounts payable, contingent consideration, and other current liabilities. The carrying amount of these financial instruments generally approximate fair value due to their short term nature. Securities available-for-sale are recorded at fair value.
	Cash and Cash Equivalents
	We consider all investments with a maturity of three months or less when acquired to be cash equivalents.
	Securities Available-for-Sale
	Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive loss in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the consolidated statements of comprehensive income (loss). The realized gains and losses on these sales were minimal for the years ended December 31, 2014 and 2013.
	The following table sets forth the composition of securities available-for-sale as of December 31, 2014 and 2013 (in thousands):
	As of December 31, 2014		Maturity in		Amortized Cost				Unrealized							Fair Value
			Years
									Gains				Losses
	Corporate debt securities		Less than 1 year		$	4,650			$	—			$	(5	)	$	4,645
	Corporate debt securities		1-3 years		3,304				—				(14		)	3,290
					$	7,954			$	—			$	(19	)	$	7,935
	As of December 31, 2013		Maturity in		Amortized Cost				Unrealized							Fair Value
			Years
									Gains				Losses
	Corporate debt securities		Less than 1 year		$	2,176			$	5			$	—		$	2,181
	Corporate debt securities		1-3 years		5,499				—				(7		)	5,492
					$	7,675			$	5			$	(7	)	$	7,673
	Allowance for Doubtful Accounts, Billing Adjustments, and Contractual Allowances
	Accounts receivable consist principally of trade receivables from customers and government or third-party healthcare insurance providers, and are generally unsecured and due within 30 days. Expected credit losses related to trade accounts receivable are recorded as an allowance for doubtful accounts within accounts receivable, net in the consolidated balance sheets. The provision for doubtful accounts is charged to general and administrative expenses. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts.
	Within Diagnostic Services, we record adjustments and credit memos that represent billing adjustments subsequent to the performance of service. A provision for billing adjustments is charged against Diagnostic Services revenues.
	Our cardiac event monitoring services are provided primarily through an independent diagnostic testing facility model which allows us to bill Medicare, Medicaid, or one of the third-party healthcare insurers directly for services provided. Accounts receivable related to cardiac event monitoring are recorded at the time revenue is recognized, net of contractual allowances. Contractual allowances are estimated based on historical collections by Current Procedural Terminology (CPT) code for specific payors, or class of payors. A provision for contractual allowances is charged against Diagnostic Services revenues.
	The following table summarizes our allowance for doubtful accounts, billing adjustments and contractual allowances as of and for the years ended December 31, 2014, 2013, and 2012 (in thousands):
			Allowance for Doubtful Accounts (1)				Reserve for Billing				Reserve for Contractual Allowances (2)
							Adjustments (2)
	Balance at December 31, 2011		$	748			$	356			$	—
	Provision adjustment		224				232				—
	Write-offs and recoveries, net		(459		)		(507		)		—
	Balance at December 31, 2012		513				81				—
	Provision adjustment		(150		)		29				—
	Write-offs and recoveries, net		(93		)		(102		)		—
	Balance at December 31, 2013		270				8				—
	Provision adjustment		571				99				18,675
	Write-offs and recoveries, net		(577		)		(100		)		(17,968		)
	Balance at December 31, 2014		$	264			$	7			$	707
	(1)	The provision was charged against general and administrative expenses.
	(2)	The provision was charged against Diagnostic Services revenue.
	Inventory
	Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis. Costs include material, labor, and manufacturing overhead costs. We rely on historical information to support our excess and obsolete reserves and utilize our business judgment with respect to estimated future demand. Per our policy, we generally reserve 100% of the cost of inventory quantities in excess of a defined period of demand. Once inventory is reserved, we do not adjust the reserve balance until the inventory is sold or disposed.
	As a result of the Diagnostic Imaging restructuring initiative announced in February 2013, we recorded approximately $1.2 million of reserve for excess and obsolete inventory for the year ended December 31, 2012.
	The following table summarizes our reserves for excess and obsolete inventory as of and for the years ended December 31, 2014, 2013, and 2012 (in thousands):
		Reserve for Excess and
		Obsolete Inventories (1)
	Balance at December 31, 2011	$	1,593
	Provision adjustment	1,164
	Write-offs and scrap	(192		)
	Balance at December 31, 2012	2,565
	Provision adjustment	210
Write-offs and scrap	(232		)
Balance at December 31, 2013	2,543
Provision adjustment	(630		)
Write-offs and scrap	—
Balance at December 31, 2014	$	1,913
(1)	The provision was charged against Diagnostic Imaging cost of revenues.
Long-Lived Assets including Finite Lived Purchased Intangible Assets
Long-lived assets consist of property and equipment and finite lived intangible assets. We record property and equipment at cost, and record other intangible assets based on their fair values at the date of acquisition. We calculate depreciation on property and equipment using the straight-line method over the estimated useful life of the assets which average 6 years for machinery and equipment, 3 years for computer hardware and software, and the lower of the lease term or an average of 5 years for leasehold improvements. Charges related to amortization of assets recorded under capital leases are included within depreciation expense. We calculate amortization on other intangible assets using either the accelerated or the straight-line method over the estimated useful life of the assets, based on when we expect to receive cash inflows generated by the intangible assets. Estimated useful lives for intangibles range from 5 to 9 years years for customer relationships, 9 years for trademarks, 8 to 15 years for patents, and 5 years for covenants not to compete.
Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. No impairment losses were recorded on long-lived assets during the years ended December 31, 2014, 2013, and 2012.
Valuation of Goodwill
We review goodwill for impairment on an annual basis during the fourth quarter, as well as when events or changes in circumstances indicate that the carrying value may not be recoverable. We begin the process by assessing qualitative factors in determining whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount. After performing the aforementioned assessment and upon review of the results of such assessment, we may begin performing step one of the two-step impairment analysis by quantitatively comparing the fair value of the reporting unit with goodwill to the carrying value of its long-term assets. If the carrying value of the long-term assets exceeds the fair value of the reporting unit, then we must perform the second step of the impairment test, whereby the carrying value of the reporting unit’s goodwill is compared to its implied fair value. If the carrying value of the goodwill exceeds the implied fair value, an impairment loss equal to the difference would be recorded.
Restricted Cash
As of December 31, 2014, we held $0.5 million of money market funds that are restricted from withdrawal as they are held as collateral for letters of credit related to our workers' compensation insurance policy and the building lease for the Poway, CA facility.
Restructuring
Restructuring costs are included in income (loss) from operations within the consolidated statements of comprehensive income (loss). Losses on property and equipment are recorded consistent with our accounting policy related to long-lived assets. One-time termination benefits are recorded at the time they are communicated to the affected employees. Losses on property lease obligations are recorded when the lease is abandoned or when the contract is terminated.
In February 2013, we announced a plan to restructure our Diagnostic Imaging business. In addition, we announced a plan in January 2014 to exit our 47,000 square foot former headquarters facility in Poway, California. Both restructuring initiatives were complete as of December 31, 2014. See Note 11 to the audited consolidated financial statements for further information.
Shipping and Handling Fees and Costs
We record all shipping and handling billings to customers as revenue earned for the goods provided. Shipping and handling costs are included in cost of revenues and totaled $0.5 million, $0.2 million, and $0.2 million for the years ended December 31, 2014, 2013, and 2012, respectively.
Share-Based Compensation
We account for share-based awards exchanged for services in accordance with the authoritative guidance for share-based compensation. Under this guidance, share-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense, net of estimated forfeitures, over the requisite service period.
Warranty
We generally provide a 12 month warranty on our gamma cameras. We accrue the estimated cost of this warranty at the time revenue is recorded and charge warranty expense to Diagnostic Imaging cost of revenues. Warranty reserves are established based on historical experience with failure rates and repair costs and the number of systems covered by warranty. Warranty reserves are depleted as gamma cameras are repaired. The costs consist principally of materials, personnel, overhead, and transportation. We review warranty reserves quarterly and, if necessary, make adjustments.
The activities related to our warranty reserve for the years ended December 31, 2014, 2013, and 2012 are as follows (in thousands):
		Year Ended December 31,
		2014				2013				2012
Balance at beginning of year		$	137			$	326			$	297
Charges to Diagnostic Imaging cost of revenues		286				149				453
Applied to liability		(247		)		(338		)		(424		)
Balance at end of year		$	176			$	137			$	326
Research and Development
Research and development costs are expensed as incurred.
Advertising Costs
Advertising costs are expensed as incurred. Total advertising costs for each of the years ended December 31, 2014, 2013, and 2012 were $0.2 million, $0.3 million, and $0.5 million, respectively.
Basic and Diluted Net Income (Loss) Per Share
Basic earnings per share (EPS) is calculated by dividing net income or loss by the weighted average number of common shares and vested restricted stock units outstanding. Diluted EPS is computed by dividing net income or loss by the weighted average number of common shares and vested restricted stock units outstanding and the weighted average number of dilutive common stock equivalents, including stock options and non-vested restricted stock units under the treasury stock method. Common stock equivalents are only included in the diluted earnings per share calculation when their effect is dilutive. Shares used to compute basic net income (loss) per share include 5,063, 44,522, and 221,335 vested restricted stock units for the years ended December 31, 2014, 2013, and 2012, respectively.
The following table sets forth the computation of basic and diluted net income (loss) per share for the periods indicated (in thousands, except per share amounts):
		Year Ended December 31,
		2014				2013				2012
Net income (loss)		$	2,475			$	264			$	(4,924	)
Shares used to compute basic net income (loss) per share		18,571				18,789				19,274
Dilutive potential common shares:
Stock options		307				359				—
Restricted stock units		—				11				—
Shares used to compute diluted net income (loss) per share		18,878				19,159				19,274
Basic net income (loss) per share		$	0.13			$	0.01			$	(0.26	)
Diluted net income (loss) per share		$	0.13			$	0.01			$	(0.26	)
Antidilutive common stock equivalents are excluded from the computation of diluted earnings per share. Stock options and restricted stock units are antidilutive when the assumed proceeds per share are greater than the average market price of the common shares. In addition, in periods where net losses are incurred, stock options and restricted stock units with assumed proceeds per share less than the average market price of the common shares become antidilutive as well.
The number of common share equivalents that were antidilutive due to the assumed proceeds per share being greater than the average market price of the common shares were 66,917, 177,891, and 268,662 for the years ended December 31, 2014, 2013, and 2012, respectively.
Since we incurred a net loss for the year ended December 31, 2012, an incremental 403,670 common share equivalents were excluded from the computation of diluted net loss per share for year ended December 31, 2012, as its effect would be antidilutive due to the net loss position.
Other Comprehensive Loss
Other comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes unrealized losses on our marketable securities.
Income Taxes
We account for income taxes in accordance with the related authoritative guidance, which sets forth an asset and liability approach that requires the recognition of deferred tax assets and deferred tax liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not expected to be realized. In making such a determination, a review of all available positive and negative evidence must be considered, including scheduled reversal of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.
The authoritative guidance for income taxes defines a recognition threshold and measurement attributes for financial statement recognition and measurement of a tax provision taken or expected to be taken in a tax return. The guidance also provides direction on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Under the guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. We recognize interest and penalties related to uncertain tax positions as a component of the income tax provision.
Acquisitions
On March 13, 2014, we acquired 100% of the membership interest of Telerhythmics, LLC (Telerhythmics), a provider of 24-hour cardiac monitoring services. We paid to the sellers of the membership interest (the Sellers) aggregate up-front consideration of $3.4 million and assumed approximately $131,000 in debt. In addition, there is an aggregate earn-out opportunity of up to $501,000 from the period March 14, 2014 through December 31, 2016 based on the Telerhythmics business meeting certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones. The acquisition was accounted for as a business combination. See Note 3 to the audited consolidated financial statements for further information.
On December 31, 2012, we acquired the operating assets of a nuclear and ultrasound imaging business located in the Southeastern U.S. The total purchase price was $500,000, including forgiveness of a $25,000 note receivable. Of the net purchase price, $340,000 was allocated to intangible assets and $135,000 to property, plant and equipment. The acquisition was accounted for as a business combination.
Accounting Standards Updates
In February 2013, the Financial Accounting Standards Board (FASB) issued guidance on disclosure requirements for items reclassified out of accumulated other comprehensive income. This new guidance requires entities to present (either on the face of the statement of operations or in the notes to the financial statements) the effects on the line items in the statement of operations for amounts reclassified out of accumulated other comprehensive income. We adopted this guidance beginning on January 1, 2013. The adoption did not have an effect on our financial condition or results of operations, and only resulted in a change to financial statement presentation and disclosure.
In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers which supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. The guidance allows for either full retrospective or modified retrospective adoption and will become effective for us in the first quarter of 2017. We are currently evaluating the alternative transition methods and the potential effects of the adoption of this guidance on our financial statements.

Supplementary_Balance_Sheet_In

Supplementary Balance Sheet Information (Notes)	12 Months Ended
	Dec. 31, 2014
Supplementary Balance Sheet Disclosures [Abstract]
Supplementary Balance Sheet Information	Supplementary Balance Sheet Information (in thousands):
			December 31,				December 31,
			2014				2013
	Inventories:
	Raw materials		$	2,439			$	2,619
	Work-in-process		2,560				3,189
	Finished goods		558				616
	Total inventories		5,557				6,424
	Less reserve for excess and obsolete inventories		(1,913		)		(2,543		)
	Total inventories, net		$	3,644			$	3,881
			December 31,				December 31,
			2014				2013
	Property and equipment:
	Machinery and equipment		$	23,412			$	22,596
	Computer hardware and software		2,917				2,497
	Leasehold improvements		571				861
	Total property and equipment		26,900				25,954
	Less accumulated depreciation		(22,134		)		(21,801		)
	Total property and equipment, net		$	4,766			$	4,153
			December 31, 2014
			Weighted Average Useful Life (years)		Gross Carrying Amount				Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with finite useful lives:
	Customer relationships		8.6		$	4,850			$	(2,904	)	$	1,946
	Trademarks		9		600				(53		)	547
	Patents		13.2		141				(116		)	25
	Covenants not to compete		5		70				(11		)	59
	Total intangible assets, net				$	5,661			$	(3,084	)	$	2,577
			31-Dec-13
			Weighted Average Useful Life (years)		Gross Carrying Amount				Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with finite useful lives:
	Customer relationships		5.3		$	2,940			$	(2,622	)	$	318
	Patents		12.6		141				(106		)	35
	Total intangible assets, net				$	3,081			$	(2,728	)	$	353
	-1	Amortization expense for intangible assets, net for the years ended December 31, 2014, 2013, and 2012 was $0.4 million, $0.2 million, and $0.2 million, respectively. Estimated amortization expense for intangible assets for 2015 is $0.4 million, for 2016 is $0.4 million, for 2017 is $0.4 million, for 2018 is $0.3 million, for 2019 is $0.3 million, and thereafter is $0.8 million.
			December 31,				December 31,
			2014				2013
	Other current liabilities:
	Professional fees		$	333			$	367
	Sales and property taxes payable		197				275
	Radiopharmaceuticals and consumable medical supplies		177				242
	Current portion of capital lease obligation		348				174
	Facilities and related costs		155				151
	Outside services and consulting		151				134
	Legal reserve		—				50
	Other accrued liabilities		428				381
	Total other current liabilities		$	1,789			$	1,774

Fair_Value_Measurements_Notes

Fair Value Measurements (Notes)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	We categorize our assets and liabilities measured at fair value into a three-level hierarchy in accordance with the authoritative guidance for fair value measurements. Assets and liabilities presented at fair value in our consolidated balance sheets are generally categorized as follows:
	Level 1:	Quoted prices in active markets for identical assets or liabilities.
	Level 2:	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3:	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Such assets and liabilities may have values determined using pricing models, discounted cash flow methodologies, or similar techniques, and include instruments for which the determination of fair value requires significant management judgment or estimation.
	As required by the authoritative guidance for fair value measurements, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of assets and liabilities and their placement within the fair value hierarchy levels. The following table sets forth by level within the fair value hierarchy our assets that were recorded at fair value as of December 31, 2014 and 2013 (in thousands):
			At Fair Value as of December 31, 2014
			Level 1		Level 2		Level 3		Total
	Assets:
	Corporate debt securities		$	—	$	4,645	$	—	$	4,645
	Liabilities:
	Acquisition related contingent consideration		$	—	$	—	$	229	$	229
			At Fair Value as of December 31, 2013
			Level 1		Level 2		Level 3		Total
	Assets:
	Corporate debt securities		$	—	$	2,181	$	—	$	2,181
	Our investments in corporate debt securities are valued based on quoted market prices for identical securities. Some of the corporate debt securities we hold do not trade on a daily basis. For investments that do not trade on a daily basis, we utilize a variety of pricing sources to determine fair value and corroborate the fair value by observing market data prior and subsequent to the balance sheet date.
	The acquisition related contingent consideration is related to our acquisition of Telerhythmics on March 13, 2014.  We reassess the fair value of the contingent consideration to be settled in cash related to our acquisition of Telerhythmics on a quarterly basis using the income approach, which is a Level 3 measurement. The estimation of the fair value of the contingent consideration requires significant management judgment, including estimating future cash flows associated with the Telerhythmics business and determining the associated discount rate. The maximum possible consideration to be paid is $501,000. No contingent consideration was earned or paid as of December 31, 2014, and no minimum amount is guaranteed to be paid.
	At the acquisition date, the contingent consideration was valued at $220,000. Upon our reassessment at December 31, 2014, we adjusted the estimated value of the contingent consideration to $229,000. The change in contingent consideration is recorded as general and administrative expense in the Consolidated Statements of Comprehensive Income (Loss). See Note 3 for further detail regarding contingent consideration related to our acquisition of Telerhythmics.

Goodwill_Notes

Goodwill (Notes)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill
	Goodwill has been recorded related to the acquisition of Ultrascan in 2007 and the acquisition of Telerhythmics in 2014. The related goodwill has been recorded within two separate reporting units within our Diagnostic Services segment. As a result of our annual impairment test during the fourth quarter of 2008, we recorded a $2.5 million impairment loss on the goodwill related to the Ultrascan acquisition, adjusting the related goodwill to its implied carrying value of $0.2 million. During the year ended December 31, 2014, we recorded $1.2 million of goodwill as a result of acquisition of Telerhythmics, bringing total goodwill to its current carrying value of $1.3 million. We determined the implied fair value of the goodwill for Telerhythmics utilizing the discounted cash flow method under the income approach. Under the income approach, we derived the fair value based on the present value of estimated future cash flows, which were based on historical data and assumptions pertaining to the market.
	During the fourth quarter of 2014, we performed our annual goodwill impairment test. We performed a qualitative assessment of all reporting units to estimate whether it is more likely than not that the fair value of each reporting unit was less than its carrying amount. In performing this qualitative assessment, we assessed relevant events and circumstances that may impact the fair value and the carrying amount of each reporting unit. Factors that were considered included, but were not limited to, the following: (1) macroeconomic conditions; (2) industry and market conditions; (3) overall financial performance and expected financial performance; (4) other entity specific events. Based on the results of this qualitative assessment, we determined that it is more likely than not that the carrying value of the Ultrascan related reporting unit is less than its fair value and, thus, the two-step quantitative analysis was not required. In regards to the Telerhythmics related reporting unit, we performed the first step of the goodwill impairment test which involves comparing the fair value of the reporting unit with the associated carrying value, including goodwill. We determined the fair value of the reporting unit using the income valuation approach. The reporting unit’s fair value exceeded the associated carrying amount of the reporting unit; therefore the second step of the goodwill impairment test was not necessary. No impairment loss was recorded for the years ended December 31, 2014, 2013, or 2012.

Commitments_And_Contingencies_

Commitments And Contingencies (Notes)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	Commitments and Contingencies
	Leases
	We currently lease facilities and certain automotive equipment under non-cancelable operating leases expiring from January 1, 2015 through November 30, 2021. Rent expense is recognized on a straight-line basis over the initial lease term and those renewal periods that are reasonably assured as determined at lease inception. The difference between rent expense and rent paid is recorded as deferred rent and is included in other current and long-term liabilities. Rent expense was approximately $1.3 million for the year ended December 31, 2014, and $1.4 million for the years ended December 31, 2013 and 2012.
	As of December 31, 2014, we financed certain information technology and medical equipment and vehicles under capital leases. These obligations are secured by the specific equipment financed under each lease and will be repaid monthly over the remaining lease terms through March 31, 2018.
	We are committed to making future cash payments on non-cancelable operating leases and capital leases (including interest). The future minimum lease payments due under both non-cancelable operating leases and capital leases having initial or remaining lease terms in excess of one year as of December 31, 2014 are as follows (in thousands):
		Operating		Capital
		Leases		Leases
	2015	$	1,108	$	383
	2016	875		308
	2017	567		123
	2018	490		5
	2019	493		—
	Thereafter	669		—
	Total minimum lease payments	$	4,202	$	819
	Radiopharmaceutical litigation. In April 2013, we settled a contractual dispute with our former radiopharmaceutical supplier who alleged that we, along with another radiopharmaceutical supplier, collaborated and breached our supply commitment contract. In summary, the settlement releases all parties from all claims associated with the dispute and the Company paid $385,000 which was recorded in other accrued liabilities as of December 31, 2012. The associated expense was recognized in the consolidated statement of comprehensive income (loss) for the year ended December 31, 2012.
	Annual Meeting Litigation. In May 2013, we were served with a complaint in Delaware Chancery Court by one of our shareholders, the Red Oak Fund, L.P. (Red Oak). In summary, the complaint alleged that the Annual Meeting of Shareholders election process (the Election) was improperly conducted. Red Oak sought to have the results of the Election voided and to compel Digirad to conduct a new Annual Meeting process. On October 23, 2013, the Delaware Chancery Court issued a memorandum opinion in favor of the Company which upheld the Election as valid.
	Other matters. In the normal course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

Share_Based_Compensation_Notes

Share Based Compensation (Notes)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share Based Compensation	Share-Based Compensation
	At December 31, 2014, we have two active equity incentive plans, the 2011 Inducement Stock Incentive Plan (the 2011 Plan) and the 2014 Equity Incentive Award Plan (the 2014 Plan), (collectively the Plans), under which stock options, restricted stock units, and other stock based awards may be granted to employees and non-employees, including members of our Board of Directors. Terms of any equity instruments granted under the Plans are approved by the Board of Directors. Stock options typically vest over the requisite service period of one to four years and have a contractual term of seven to ten years. Restricted stock units generally vest over one to four years. Under the Plans, we are authorized to issue an aggregate of 1,856,733 shares of common stock. As of December 31, 2014, the Plans had 1,131,432 shares available for future issuance. The number of shares reserved for issuance under the 2014 Plan is subject to increase by any shares under the 2004 Equity Incentive Award Plan (the 2004 Plan) that are forfeited, expire, or are canceled. As of December 31, 2014, the number of shares provided for issuance under the 2014 Plan due to forfeited, expired, and canceled shares under the 2004 Plan was 1,500 shares.
	Stock Options
	The estimated fair value of our stock options is determined using the Black-Scholes model. All stock options were granted with an exercise price equal to the fair value of the common stock on the grant date. The weighted-average grant date fair value of employee stock options granted during the years ended December 31, 2014, 2013, and 2012 was $0.70, $1.06, and $1.05 per share, respectively, which was estimated using the following weighted-average assumptions:
		Year Ended December 31,
		2014		2013			2012
	Expected volatility	43	%	56	%		59	%
	Expected term (in years)	4.1		4.6			6
	Risk-free interest rate	1.2	%	0.9	%		1.2	%
	Expected dividend yield	5.7	%	—			—
	The determination of the fair value of stock options using an option valuation model is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. The volatility assumption is based on the historical volatility of our common stock over a period of time equal to the expected term of the stock options. The expected term of our stock options is based on historical experience. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield in effect at the time of grant. The expected dividend yield is based on the current annualized dividend rate per share divided by the historical average stock price. At the time of the grants, for the years ended December 31, 2013 and 2012, we had no plans to pay a dividend and no history of paying a dividend previously and as such an expected dividend yield of zero was utilized for purposes of determining fair value of the associated stock options.
	A summary of our stock option award activity as of and for the year ended December 31, 2014 is as follows (in thousands, except per share data):
		Number of		Weighted-				Weighted-		Aggregate
		Shares		Average				Average		Intrinsic  Value
				Exercise				Remaining
				Price per				Contractual
				Share				Term (In Years)
	Options outstanding at December 31, 2013	856		$	1.93
	Options exercisable at December 31, 2013	501		$	1.75
	Options granted	750		$	3.38
	Options forfeited	(45	)	3.21
	Options expired	(5	)	6.98
	Options exercised	(98	)	1.92
	Options outstanding at December 31, 2014	1,458		$	2.62			5		$	2,537
	Options exercisable at December 31, 2014	553		$	1.82			3.4		$	1,403
	As share-based compensation expense under the authoritative guidance for share-based payments is based on awards ultimately expected to vest, it is reduced for estimated forfeitures. The guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	At December 31, 2014, total unrecognized compensation cost related to unvested stock options was $0.5 million, which is expected to be recognized over a weighted-average period of 1.8 years.
	Upon exercise, we issue new shares of common stock. Cash received from stock option exercises was $0.2 million during the year ended December 31, 2014, $0.9 million during the year ended December 31, 2013, and $0.3 million for the year ended December 31, 2012. We did not recognize any income tax benefits from stock option exercises as we continue to record a valuation allowance on our deferred tax assets, as more fully described in Note 9. The total intrinsic value of stock options exercised was $0.1 million during the year ended December 31, 2014, $0.9 million during the year ended December 31, 2013, and less than $0.1 million during the year ended 2012.
	Restricted Stock Units
	Under guidance for share-based payments, the fair value of our restricted stock awards is based on the grant date fair value of our common stock. All restricted stock units were granted with no purchase price. Vesting of the restricted stock awards is subject to service conditions, as well as the attainment of additional performance objectives for certain of the awards. The weighted-average grant date fair value of the restricted stock units was $3.81 and $1.82 per share during the years ended December 31, 2014 and 2012, respectively. There were no restricted stock units granted during the year ended December 31, 2013.
	A summary of our restricted stock unit activity as of and for the year ended December 31, 2014 is as follows (in thousands, except per share data):
		Number of		Weighted-
		Shares		Average
				Grant Date
				Fair Value
				Per Share
	Non-vested restricted stock units outstanding at December 31, 2013	—		$	—
	Granted	88		3.81
	Forfeited	—		—
	Vested	—		—
	Non-vested restricted stock units outstanding at December 31, 2014	88		$	—
	The following table summarizes information about restricted stock units that vested during the years ended December 31, 2014, 2013, and 2012 based on service conditions (in thousands):
		Year Ended December 31,
		2014			2013				2012
	Fair value on vesting date of vested restricted stock units	$	—		$	136			$	350
	At December 31, 2014, total unrecognized compensation cost related to non-vested restricted stock units was $0.3 million, which is expected to be recognized over a weighted-average period of 3.5 years.
	Allocation of Share-Based Compensation Expense
	Total share-based compensation expense related to all of our share-based units for the years ended December 31, 2014, 2013, and 2012 was allocated as follows (in thousands):
		Year Ended December 31,
	Cost of revenues:	2014			2013				2012
	Diagnostic Services	$	1		$	6			$	7
	Diagnostic Imaging	26			49				82
	Research and development	—			9				78
	Marketing and sales	51			52				127
	General and administrative	248			224				336
	Share-based compensation expense	$	326		$	340			$	630

Income_Taxes_Notes

Income Taxes (Notes)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	Significant components of the provision (benefit) for income taxes are as follows (in thousands):
		Year Ended December 31,
		2014				2013				2012
	Current provision (benefit):
	Federal	$	—			$	(49	)		$	(128	)
	State	41				4				51
	Total current provision (benefit)	41				(45		)		(77		)
	Deferred provision:
	Federal	18				—				—
	State	3				—				—
	Total deferred provision	21				—				—
	Total income tax provision (benefit)	$	62			$	(45	)		$	(77	)
	Differences between the provision (benefit) for income taxes and income taxes at the statutory federal income tax rate are as follows:
		Year Ended December 31,
		2014			2013			2012
	Income tax expense (benefit) at statutory federal rate	35	%		35	%		(35.0	)%
	State income tax expense (benefit), net of federal benefit	4.8	%		7.2	%		(2.9	)%
	Permanent differences and other	(2.9	)%		14.8	%		1.4	%
	Research and development credits, current year	—	%		(58.1	)%		(2.6	)%
	Research and development credits, prior year	—	%		(39.1	)%		—	%
	Change in effective state tax rates	(3.2	)%		(25.6	)%		2.4	%
	Expiration of net operating loss carryovers	1.1	%		8.2	%		36.6	%
	Stock compensation expense	0.1	%		53.7	%		—	%
	Reserve for uncertain tax positions and other reserves	—	%		5.4	%		(2.4	)%
	Change in valuation allowance	(32.5	)%		(22.2	)%		1	%
	Provision (benefit) for income taxes	2.4	%		(20.7	)%		(1.5	)%
	As of December 31, 2014, we had federal and state income tax net operating loss carryforwards of $93.2 million and $28.0 million, respectively. Federal loss carryforwards will begin to expire in 2018 unless previously utilized. State loss carryforwards of less than $0.1 million expired in 2014, and approximately $4.1 million is set to expire in 2015 unless previously utilized. We also have federal and California research and other credit carryforwards of approximately $1.8 million and $2.1 million, as of December 31, 2014, respectively. The federal credits will begin to expire in 2018. The California research credits have no expiration. Pursuant to Internal Revenue Code Sections 382 and 383, use of our net operating loss and credit carryforwards may be limited because of a cumulative change in ownership greater than 50% which may have occurred or which may occur in the future.
	Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December 31, 2014. Such objective evidence limits the ability to consider other subjective evidence such as our projections for future income. On the basis of this evaluation, as of December 31, 2014, a valuation allowance has been recorded as management cannot conclude that it is more likely than not that the existing deferred tax assets will be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence such as our projected future income.
	Our net deferred tax assets (liabilities) consisted of the following (in thousands):
		December 31,
		2014				2013
	Deferred tax assets (liabilities):
	Net operating loss carryforwards	$	33,732			$	34,727
	Research and development and other credits	1,950				1,928
	Reserves	1,417				1,273
	Intangibles	2,097				2,425
	Other, net	1,079				830
	Total deferred tax assets	40,275				41,183
	Deferred tax liabilities—depreciation	(237		)		(300		)
	Valuation allowance for deferred tax assets	(40,059		)		(40,883		)
	Net deferred tax assets (liabilities)	$	(21	)		$	—
	The following table summarizes the activity related to our unrecognized tax benefits (in thousands):
		December 31,
		2014				2013				2012
	Balance at beginning of year	$	1,553			$	1,539			$	1,621
	Increases related to prior year tax positions	—				5				25
	Increases related to current year tax positions	—				64				81
	Expiration of the statute of limitations for the assessment of taxes	—				(55		)		(252		)
	Change in valuation allowances	—				—				64
	Balance at end of year	$	1,553			$	1,553			$	1,539
	Included in the unrecognized tax benefits of $1.6 million at December 31, 2014 was $1.3 million of tax benefits that, if recognized, would reduce our annual effective tax rate, subject to the valuation allowance. We do not expect our unrecognized tax benefits to change significantly over the next 12 months.
	We file income tax returns in the U.S. and in various state jurisdictions with varying statutes of limitations. We are no longer subject to income tax examination by tax authorities for years prior to 2009; however, our net operating loss carryforward and research credit carryforwards arising prior to that year are subject to adjustment. Our policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There were no accrued interest and penalties as of December 31, 2014 and 2013 ,and no interest and penalties were recognized during the years ended December 31, 2014, 2013, and 2012.

Employee_Retirement_Plan_Notes

Employee Retirement Plan (Notes)	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Employee Retirement Plan	Employee Retirement Plan
	We have 401(k) retirement plans under which employees may contribute up to 100% of their annual salary, within IRS limits. The Company contributions to the retirement plans totaled $0.2 million for each of the years ended December 31, 2014, 2013, and 2012.

Restructuring_Charges_Notes

Restructuring Charges (Notes)	12 Months Ended
	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Restructuring Charges	NOTE 11.     Restructuring Charges
	Facilities restructuring initiative
	On January 27, 2014, we announced a plan to exit our 47,000 square foot former headquarters facility in Poway, California (the Facilities restructuring initiative). This action was undertaken as the facility had excess space and capacity given our current operating plan. We entered into a termination agreement to end the lease on the facility as of April 30, 2014. The original term of the lease would have continued through February 29, 2016. Concurrently with the termination of the lease for the 47,000 square foot Poway, California facility, we entered into a new lease agreement on January 23, 2014 for a separate 21,300 square foot facility in Poway, California to house our Diagnostic Imaging operations.
	As a result of the Facilities restructuring initiative, we incurred a total of $0.7 million of restructuring charges, all of which were incurred during the year ended December 31, 2014. The charges are comprised of lease termination, moving and other related costs. All restructuring efforts associated with this initiative were complete as of December 31, 2014.
	The following table includes information regarding our Facilities restructuring initiative:
	(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at December 31, 2014
	Total Facilities restructuring initiative	$	—	$	663	$	660	$	3
	Accrued Facilities restructuring initiative charges at December 31, 2014 are included in the accounts payable line item in the consolidated balance sheets. All Facilities restructuring initiative charges for the year ended December 31, 2014 are included in the Diagnostic Imaging segment.
	Diagnostic Imaging restructuring initiative
	On February 28, 2013, we announced a plan to restructure our Diagnostic Imaging business to significantly reduce costs and focus on maximizing cash flow from our Diagnostic Services business (the Diagnostic Imaging restructuring initiative). The Diagnostic Imaging restructuring initiative included a reduction in force. In addition, as part of the Diagnostic Imaging restructuring initiative, we entered into an agreement in September 2013 with a third party to outsource the majority of the manufacturing associated with our cameras. As a result of the Diagnostic Imaging restructuring initiative, we incurred a total of $1.8 million in restructuring charges, the majority of which were incurred during fiscal year 2013. Included in the total Diagnostic Imaging restructuring initiative charges are $1.6 million of employee related costs, with the remaining costs consisting of contract termination costs and other related costs. All restructuring efforts associated with this initiative were complete as of June 30, 2014.
	The following table includes information regarding our Diagnostic Imaging restructuring initiative:
	(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at December 31, 2014
	Total Diagnostic Imaging restructuring initiative	$	489	$	29	$	516	$	2
	All accrued Diagnostic Imaging restructuring initiative charges at December 31, 2014 are included in the accrued compensation line item in the consolidated balance sheets. All the Diagnostic Imaging restructuring initiative charges for the year ended December 31, 2014 are included in the Diagnostic Imaging segment.

Surgical_Imaging_Asset_Sale_an

Surgical Imaging Asset Sale and License Agreement (Notes)	12 Months Ended
	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Surgical Imaging Asset Sale and License Agreement	Surgical Imaging Asset Sale and License Agreement
	On July 31, 2013, we entered into an asset purchase agreement with Novadaq Technologies Inc. (Novadaq). Under the terms of the asset purchase agreement, we sold Novadaq all of our assets specifically related to an uncommercialized surgical imaging system previously in development. We also licensed certain existing Company technology to Novadaq for their use in the peri-operative field. In exchange, we received upfront consideration of $2.0 million, and could receive up to $1.0 million in deferred contingent payments based on the achievement of specific regulatory and commercial milestones. In addition a royalty on sales, if any, will be paid for a period of five years from the date of the first commercial sale of the related surgical imaging system.
	We identified the deliverables at the inception of the agreements and determined that the tangible assets, consisting of inventory parts, and intangible assets, consisting of the technology license and various patents and know-how, individually represent separate units of accounting because each deliverable has standalone value. The best estimated selling prices for these units of accounting were determined using the income method for the intangible assets, and cost plus a reasonable margin basis for the tangible assets. The arrangement consideration was allocated to the deliverables based on the relative selling price method.
	The amount of allocable arrangement consideration is limited to the amount that is not contingent upon meeting other specified performance conditions (the non-contingent amount); therefore, the amount allocated to the deliverables was limited to the upfront cash received of $2.0 million. A gain of $1.6 million representing the $2.0 million of upfront consideration less legal, consulting, and other transaction fees, as well as the cost basis of the inventory was recorded during the year ended December 31, 2013.
	We expect to recognize the regulatory and commercial milestone payments as a gain if and when the milestones are achieved. We expect to recognize the sales royalty payments as a gain if and when the royalties are earned.

Stock_Repurchase_Program_Notes

Stock Repurchase Program (Notes)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stock Repurchase Program	Stock Repurchase Program
	On February 27, 2013, our board of directors modified our stock buyback program originally adopted in February 2009 to increase repurchases to an aggregate of $7.0 million, and subsequently, on March 13, 2013, increased the stock buyback program again for repurchases of up to an aggregate of $12.0 million. During the years ended December 31, 2013 and 2012, we repurchased 1,514,843 and 490,816 shares of our common stock, respectively, under the stock buyback program. During the year ended December 31, 2014, we did not repurchase any of our common stock. As of December 31, 2014, an aggregate of $6.3 million remains authorized for stock buyback under the program.

Preferred_Stock_Rights_Notes

Preferred Stock Rights (Notes)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Preferred Stock Rights	Preferred Stock Rights
	On May 23, 2013, the Company's Board of Directors adopted a tax benefit preservation plan in the form of a Section 382 Rights Agreement (the 382 Agreement). The 382 Agreement is intended to diminish the risk that our ability to use our net operating loss carryforwards to reduce future federal income tax obligations may become substantially limited due to an “ownership change,” as defined in Section 382 of the Internal Revenue Code. The Board authorized and declared a dividend distribution of one right for each outstanding share of common stock, par value $0.0001 per share, of the Company to stockholders of record as of the close of business on June 4, 2013. Each right entitles the registered holder to purchase from the Company one one-thousandth of a share of Series B Participating Preferred Stock, par value $0.0001 per share, of the Company at an exercise price of $20.00 per one one-thousandth of a Preferred Share, subject to adjustment.
	The rights will become exercisable following (i) the 10th business day (or such later date as may be determined by the Board of Directors) after the public announcement that an acquiring person has acquired beneficial ownership of 4.99% or more of the common shares of the Company or (ii) the 10th business day (or such later date as may be determined by the Board of Directors) after a person or group announces a tender or exchange offer that would result in ownership by a person or group of 4.99% or more of the common shares of the Company.
	In addition, upon the occurrence of certain events, the exercise price of the rights would be adjusted and holders of the rights (other than rights owned by an acquiring person or group) would be entitled to purchase common stock at approximately half of market value. Given the potential adjustment of the exercise price of the rights, the rights could cause substantial dilution to a person or group that acquires 4.99% or more of the Company's common stock on terms not approved by the Company's Board of Directors.
	No rights were exercisable at December 31, 2014. There is no impact to the Company's financial results as a result of the adoption of the rights plan for the years ended December 31, 2014 and 2013.

Segments_Notes

Segments (Notes)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segments	Segments
	Our reporting segments have been determined based on the nature of the products and/or services offered to customers or the nature of their function in the organization. We evaluate performance based on the operating income (loss) contributed by each segment. Our operating segments include Diagnostic Imaging, Digirad Imaging Solutions, and cardiac event monitoring from our Telerhythmics acquisition on March 13, 2014 (See Note 3). For financial reporting purposes, we aggregate Digirad Imaging Solutions and cardiac event monitoring due to their similar economic and operational characteristics. Summarized annual data for segments are as follows (in thousands):
		Year ended December 31,
		2014 (1)		2013		2012
	Gross profit by segment:
	Diagnostic Services	$	10,449	$	9,343	$	8,771
	Diagnostic Imaging	6,191		4,773		4,321
	Consolidated gross profit	$	16,640	$	14,116	$	13,092
	Income (loss) from operations by segment:
	Diagnostic Services	$	220	$	30	$	(48	)
	Diagnostic Imaging (2)	2,298		141		(5,050		)
	Consolidated income (loss) from operations	$	2,518	$	171	$	(5,098	)
	Depreciation and amortization of tangible and intangible assets by segment:
	Diagnostic Services	$	1,672	$	1,436	$	1,814
	Diagnostic Imaging	263		477		317
	Consolidated depreciation and amortization	$	1,935	$	1,913	$	2,131
		December 31,
		2014 (1)		2013
	Identifiable assets by segment:
	Diagnostic Services	$	18,724	$	11,874
	Diagnostic Imaging	23,177		29,577
	Consolidated assets	$	41,901	$	41,451
	(1) On March 13, 2014, we acquired 100% of the membership interest of Telerhythmics, LLC. The results of Telerhythmics are included in Diagnostic Services since the acquisition date (See Note 3).
	(2) Included in the Diagnostic Imaging income from operations for the year ended December 31, 2014, are approximately $0.7 million of charges associated with our Diagnostic Imaging and Facilities restructuring initiatives (See Note 11). Included in the Diagnostic Imaging income from operations for the year ended December 31, 2013, are approximately $1.7 million of charges associated with our Diagnostic Imaging restructuring initiative, as well as a gain of approximately $1.6 million associated with the sale of assets and licensing agreement from an uncommercialized surgical imaging system previously in development (See Note 12).

Quaterly_Financial_Information

Quaterly Financial Information (Unaudited) (Notes)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information	Quarterly Financial Information (Unaudited)
	The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for fiscal 2014 and 2013 are as follows (in thousands, except per share data):
			1st			2nd			3rd		4th
			Quarter			Quarter			Quarter		Quarter
	Fiscal 2014 (1)
	Revenues		$	12,997		$	14,587		$	13,881	$	14,143
	Gross profit		$	3,442		$	4,505		$	4,409	$	4,284
	Income (loss) from operations (2)		$	(155	)	$	825		$	1,032	$	816
	Net income (loss)		$	(148	)	$	823		$	1,028	$	772
	Net income (loss) per common share—basic (3)		$	(0.01	)	$	0.04		$	0.06	$	0.04
	Net income (loss) per common share—diluted (3)		$	(0.01	)	$	0.04		$	0.05	$	0.04
	Fiscal 2013
	Revenues		$	11,546		$	12,890		$	12,413	$	12,527
	Gross profit		$	2,817		$	3,793		$	3,818	$	3,688
	Income (loss) from operations		$	(2,409	)	$	(632	)	$	2,432	$	780
	Net income (loss)		$	(2,419	)	$	(616	)	$	2,512	$	787
	Net income (loss) per common share—basic (3)		$	(0.13	)	$	(0.03	)	$	0.14	$	0.04
	Net income (loss) per common share—diluted (3)		$	(0.13	)	$	(0.03	)	$	0.14	$	0.04
	(1)	On March 13, 2014, we acquired 100% of the membership interest of Telerhythmics, LLC. The results of Telerhythmics are included in Diagnostic Services since the acquisition date (See Note 3).
	(2)	Included in the income (loss) from operations for the first, second, third, and fourth quarter of 2014, are approximately $0.4 million, $0.1 million, $0.1 million, and less than $0.1 million of charges, respectively, associated with our Diagnostic Imaging and Facilities restructuring initiatives (See Note 11).
	(3)	Earnings per share are computed independently for each of the quarters presented. Therefore, the sum of the quarterly net earnings per share will not necessarily equal the total for the year.

Subsequent_Event_Notes

Subsequent Event (Notes)	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events
	Dividend
	On February 2, 2015, the Company announced a dividend of $0.05 payable to shareholders of record as of February 13, 2015. The dividend was paid on February 23, 2015.
	MD Office Solutions, Inc. Acquisition
	On March 5, 2015, we entered into an Agreement of Merger and Plan of Reorganization (the Merger Agreement) with the Stockholders party thereto (Sellers), to acquire MD Office Solutions, Inc. (MD Office).
	Total consideration related to the Merger Agreement paid to the Sellers was 610,000 shares of common stock of Digirad Corporation, with a total value at closing of $2,684,000. The Company issued new shares for the consideration. In addition, there is an earn-out opportunity of up to $400,000 in cash over approximately three years based on the MD Office business meeting certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones. The Sellers will receive fifty percent of the EBITDA generated by the MD Office business in excess of the EBITDA milestone amounts, which is $650,000 for each of the annual periods ending December 31, 2015, 2016 and 2017, with the target for 2015 being prorated based on the close date. The Merger Agreement is also subject to a post-closing purchase price adjustment based on the final working capital balance, as defined in the Merger Agreement, as well as a Registration Rights Agreement related to the common shares provided to the Sellers as part of the consideration.
	We expect to account for the transaction as a business combination and are in the process of determining the allocation of the purchase price to acquired assets and assumed liabilities, as well as preparing pro forma financial information. A determination of the acquisition-date fair values of the assets acquired and the liabilities assumed is pending the completion of an independent appraisal and other evaluations and therefore further disclosures have not been made.

Acquisition_of_Telerhythmics_N

Acquisition of Telerhythmics (Notes)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Acquisition of Telerhythmics, LLC	Acquisition of Telerhythmics, LLC
	On March 13, 2014, we acquired 100% of the membership interest of Telerhythmics, LLC (Telerhythmics), a provider of 24-hour cardiac monitoring services. Telerhythmics and Digirad each have a very similar customer base, yet with only minor overlaps in current customers. We believe this similar customer base will allow us to leverage each company’s strengths to grow sales and also diversify Digirad’s service offerings.
	We paid to the sellers of the membership interest (the Sellers) aggregate up-front consideration of $3.4 million and assumed approximately $131,000 in debt. In addition, there is an aggregate earn-out opportunity of up to $501,000 from the period March 14, 2014 through December 31, 2016 based on the Telerhythmics business meeting certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones. The Sellers will receive fifty percent (50%) of the EBITDA generated by the Telerhythmics business in excess of the EBITDA milestone amounts, which are as follows:
	•	$415,000 of EBITDA for the period from the closing date through December 31, 2014,
	•	$825,000 of EBITDA for the period from January 1, 2015 through December 31, 2015; and
	•	$825,000 of EBITDA for the period from January 1, 2016 through December 31, 2016.
	At December 31, 2014, we have estimated the fair value of the contingent earn-out opportunity to be $229,000. The earn-out opportunity is estimated based on expected performance of the business over the period from January 1, 2015 through December 31, 2016, utilizing an income approach. No earn-out consideration was earned by the Sellers for the period from the closing date through December 31, 2014. It is reasonably possible that our estimate of the earn-out potential could change in the near term. Any adjustment in the estimated earn-out opportunity until settled will be recorded as a gain or loss to current operations in the period the estimate changes.
	As of December 31, 2014, the allocation of the purchase price to the assets acquired and liabilities assumed on the acquisition date was as follows (in thousands):
			Allocation of purchase price
	Assets
	Current assets:
	Accounts receivable, net		$	256
	Other current assets		34
	Total current assets		290
	Property and equipment, net		290
	Intangible assets, net		2,580
	Goodwill		1,153
	Total assets		$	4,313
	Liabilities
	Current liabilities:
	Accounts payable		$	36
	Accrued compensation		169
	Other accrued liabilities		356
	Current portion of long-term debt		131
	Total current liabilities		692
	Other liabilities		174
	Total liabilities		$	866
	The long-term debt was paid in full on March 28, 2014.
	The goodwill recognized as part of the transaction primarily represents synergies between Digirad and Telerhythmics that were not separately identified as part of the acquisition valuation process. Telerhythmics activities are considered their own operating segment, which is aggregated into our Diagnostic Services reportable segment (formerly Digirad Imaging Solutions). The resulting goodwill from the acquisition is expected to be deductible for federal and state tax reporting purposes.
	The below tables display estimated pro forma results had the business acquisition been completed as of January 1, 2013. In deriving the pro forma results, we utilized the historical operating results of Telerhythmics and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2013.
		Year Ended December 31,
		(unaudited)
	(in thousands)	2014			2013
	Revenues	$	56,763		$	55,494
	Net income	$	2,688		$	247
	Included within our consolidated operating results for the year ended December 31, 2014 are Telerhythmics operations for the period March 14, 2014 through December 31, 2014 as follows:
	(in thousands)	Year Ended
		31-Dec-14
		(unaudited)
	Revenues	$	3,926
	Net loss	$	(777	)
	Included within the results for Telerhythmics is approximately $155,000 of transaction costs related to the acquisition. These costs are classified as general and administrative expenses in the consolidated statements of comprehensive income (loss).

Basis_Of_Presentation_And_Sign1

Basis Of Presentation And Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Basis of Presentation and Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The consolidated financial statements are prepared in conformity with United States generally accepted accounting principles (GAAP) and include the financial statements of the Company and its wholly owned subsidiaries. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported amounts of revenues and expenses. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results could differ from management’s estimates. All significant intercompany accounts and transactions have been eliminated.
	The financial results for the year ended December 31, 2014 include the financial results of Telerhythmics, LLC for the period since the acquisition date of March 13, 2014. See Note 3 to the audited consolidated financial statements for more information related to the acquisition of Telerhythmics, LLC.
Revenue Recognition	Revenue Recognition
	We derive revenues primarily from providing in-office services related to the performance of cardiac diagnostic imaging procedures, cardiac event monitoring, and from selling and servicing solid-state digital gamma cameras. We recognize revenue in accordance with the authoritative guidance for revenue recognition, when all of the following four criteria are met: (i) a contract or sales arrangement exists; (ii) products have been shipped and title has transferred or services have been rendered; (iii) the price of the products or services is fixed or determinable; and (iv) collectability is reasonably assured. The timing of revenue recognition is based upon factors such as passage of title and risk of loss, the need for installation, and customer acceptance. These factors are based on the specific terms of each contract or sales arrangement.
	Diagnostic Services imaging services revenue is derived from our ability to provide our physician customers with our services, which includes use of our imaging system, qualified personnel, and related items required to perform imaging in their own offices and bill Medicare, Medicaid, and other payors for in-office nuclear and ultrasound diagnostic imaging procedures. Revenue related to Diagnostic Imaging services is recognized at the time services are performed and collection is reasonably assured. Diagnostic Services imaging services are generally billed on a per-day basis under annual contracts for nuclear diagnostic imaging, which specify the number of days of service to be provided, or on a flat rate month-to-month basis for ultrasound imaging.
	Our cardiac event monitoring services are provided primarily through an independent diagnostic testing facility model which allows us to bill Medicare, Medicaid, or one of the third-party healthcare insurers directly for services provided. We also receive reimbursement directly from patients through co-pays and self-pay arrangements. Billings for services reimbursed by third-party payors, including Medicare, are recorded as revenue net of contractual allowances. Contractual allowances are estimated based on historical collections by Current Procedural Terminology (CPT) code for specific payors, or class of payors. Adjustments to the estimated receipts, based on final settlement with the third party payors, are recorded upon settlement.
	Diagnostic Imaging product revenues are generated from the sales of gamma cameras and follow-on maintenance service contracts. We generally recognize revenue upon delivery and acceptance by customers. We also provide installation and training for camera sales in the United States. Installation and initial training is generally performed shortly after delivery and represents a cost which we accrue at the time revenue is recognized. Neither service is essential to the functionality of the product. Maintenance services are sold beyond the term of the warranty, which is generally one year from the date of purchase. Revenue from these contracts is deferred and recognized ratably over the period of the obligation and is included in Diagnostic Imaging sales.
	Multiple Element Arrangements
	In fiscal year 2013, we sold all of our assets specifically related to an uncommercialized surgical imaging system previously in development, as well as licensed certain existing Company technology. The transaction was accounted for in accordance with the authoritative guidance for multiple element arrangements. We identified the deliverables at the inception of the agreement and determined which items had value to the customer on a standalone basis, and were therefore separate units of accounting. Non-contingent arrangement consideration was allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each unit of accounting was determined using best estimate of selling price, because neither vendor specific objective evidence (VSOE) of selling price nor third-party evidence of selling price existed for the units of accounting. The non-contingent amount of arrangement consideration allocated to each unit of account was recognized upon performance and delivery of the related unit of accounting.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosures made in the accompanying notes to the consolidated financial statements. Significant estimates and judgments include those related to revenue recognition, multiple element arrangements, reserves for doubtful accounts and contractual allowances, and inventory valuation. Actual results could differ from those estimates.
Concentration of Credit Risk and Significant Customers	Concentration of Credit Risk and Significant Customers
	Financial instruments, which potentially subject us to concentrations of credit risk, consist primarily of cash and cash equivalents, short-term investments, and accounts receivable. We limit our exposure to credit loss by placing our cash and investments in high credit quality financial institutions and investment grade corporate debt securities. Additionally, we have established guidelines regarding diversification of our investments and their maturities, which are designed to maintain principal and maximize liquidity.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The authoritative guidance for fair value measurements defines fair value for accounting purposes, establishes a framework for measuring fair value, and provides disclosure requirements regarding fair value measurements. The guidance defines fair value as an exit price, which is the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date. The degree of judgment utilized in measuring the fair value of assets and liabilities generally correlates to the level of pricing observability. Our financial instruments primarily consist of cash equivalents, securities available-for-sale, accounts receivable, other current assets, restricted cash, accounts payable, contingent consideration, and other current liabilities. The carrying amount of these financial instruments generally approximate fair value due to their short term nature. Securities available-for-sale are recorded at fair value.
Cash and Cash Equivalents	Cash and Cash Equivalents
	We consider all investments with a maturity of three months or less when acquired to be cash equivalents.
Securities Available-for-sale	Securities Available-for-Sale
	Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive loss in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the consolidated statements of comprehensive income (loss).
Allowance for Doubtful Accounts, Billing Adjustments, and Contractual Allowances	Allowance for Doubtful Accounts, Billing Adjustments, and Contractual Allowances
	Accounts receivable consist principally of trade receivables from customers and government or third-party healthcare insurance providers, and are generally unsecured and due within 30 days. Expected credit losses related to trade accounts receivable are recorded as an allowance for doubtful accounts within accounts receivable, net in the consolidated balance sheets. The provision for doubtful accounts is charged to general and administrative expenses. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts.
Inventory	Inventory
	Our inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value) and we review inventory balances for excess and obsolete inventory levels on a quarterly basis. Costs include material, labor, and manufacturing overhead costs. We rely on historical information to support our excess and obsolete reserves and utilize our business judgment with respect to estimated future demand. Per our policy, we generally reserve 100% of the cost of inventory quantities in excess of a defined period of demand. Once inventory is reserved, we do not adjust the reserve balance until the inventory is sold or disposed.
Long-Lived Assets including Finite Lived Purchased Intangible Assets	Long-Lived Assets including Finite Lived Purchased Intangible Assets
	Long-lived assets consist of property and equipment and finite lived intangible assets. We record property and equipment at cost, and record other intangible assets based on their fair values at the date of acquisition. We calculate depreciation on property and equipment using the straight-line method over the estimated useful life of the assets which average 6 years for machinery and equipment, 3 years for computer hardware and software, and the lower of the lease term or an average of 5 years for leasehold improvements. Charges related to amortization of assets recorded under capital leases are included within depreciation expense. We calculate amortization on other intangible assets using either the accelerated or the straight-line method over the estimated useful life of the assets, based on when we expect to receive cash inflows generated by the intangible assets.
Valuation of Long Lived Assets including Finite Lived Purchased Intangible Assets	Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.
Valuation of Goodwill	Valuation of Goodwill
	We review goodwill for impairment on an annual basis during the fourth quarter, as well as when events or changes in circumstances indicate that the carrying value may not be recoverable. We begin the process by assessing qualitative factors in determining whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount. After performing the aforementioned assessment and upon review of the results of such assessment, we may begin performing step one of the two-step impairment analysis by quantitatively comparing the fair value of the reporting unit with goodwill to the carrying value of its long-term assets. If the carrying value of the long-term assets exceeds the fair value of the reporting unit, then we must perform the second step of the impairment test, whereby the carrying value of the reporting unit’s goodwill is compared to its implied fair value. If the carrying value of the goodwill exceeds the implied fair value, an impairment loss equal to the difference would be recorded.
Restricted Cash	Restricted Cash
	As of December 31, 2014, we held $0.5 million of money market funds that are restricted from withdrawal as they are held as collateral for letters of credit related to our workers' compensation insurance policy and the building lease for the Poway, CA facility.
Restructuring	Restructuring
	Restructuring costs are included in income (loss) from operations within the consolidated statements of comprehensive income (loss). Losses on property and equipment are recorded consistent with our accounting policy related to long-lived assets. One-time termination benefits are recorded at the time they are communicated to the affected employees. Losses on property lease obligations are recorded when the lease is abandoned or when the contract is terminated.
Shipping and Handling Fees and Costs	Shipping and Handling Fees and Costs
	We record all shipping and handling billings to customers as revenue earned for the goods provided. Shipping and handling costs are included in cost of revenues
Share-Based Compensation	Share-Based Compensation
	We account for share-based awards exchanged for services in accordance with the authoritative guidance for share-based compensation. Under this guidance, share-based compensation expense is measured at the grant date, based on the estimated fair value of the award, and is recognized as expense, net of estimated forfeitures, over the requisite service period.
Warranty	Warranty
	We generally provide a 12 month warranty on our gamma cameras. We accrue the estimated cost of this warranty at the time revenue is recorded and charge warranty expense to Diagnostic Imaging cost of revenues. Warranty reserves are established based on historical experience with failure rates and repair costs and the number of systems covered by warranty. Warranty reserves are depleted as gamma cameras are repaired. The costs consist principally of materials, personnel, overhead, and transportation. We review warranty reserves quarterly and, if necessary, make adjustments.
Research and Development	Research and Development
	Research and development costs are expensed as incurred.
Advertising Costs	Advertising Costs
	Advertising costs are expensed as incurred.
Basic and Diluted Net Income (Loss) Per Share	Basic and Diluted Net Income (Loss) Per Share
	Basic earnings per share (EPS) is calculated by dividing net income or loss by the weighted average number of common shares and vested restricted stock units outstanding. Diluted EPS is computed by dividing net income or loss by the weighted average number of common shares and vested restricted stock units outstanding and the weighted average number of dilutive common stock equivalents, including stock options and non-vested restricted stock units under the treasury stock method. Common stock equivalents are only included in the diluted earnings per share calculation when their effect is dilutive.
Other Comprehensive Income (Loss)	Other Comprehensive Loss
	Other comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss includes unrealized losses on our marketable securities.
Income Taxes	Income Taxes
	We account for income taxes in accordance with the related authoritative guidance, which sets forth an asset and liability approach that requires the recognition of deferred tax assets and deferred tax liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not expected to be realized. In making such a determination, a review of all available positive and negative evidence must be considered, including scheduled reversal of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.
	The authoritative guidance for income taxes defines a recognition threshold and measurement attributes for financial statement recognition and measurement of a tax provision taken or expected to be taken in a tax return. The guidance also provides direction on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Under the guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. We recognize interest and penalties related to uncertain tax positions as a component of the income tax provision.
Acquisition	Acquisitions
	On March 13, 2014, we acquired 100% of the membership interest of Telerhythmics, LLC (Telerhythmics), a provider of 24-hour cardiac monitoring services. We paid to the sellers of the membership interest (the Sellers) aggregate up-front consideration of $3.4 million and assumed approximately $131,000 in debt. In addition, there is an aggregate earn-out opportunity of up to $501,000 from the period March 14, 2014 through December 31, 2016 based on the Telerhythmics business meeting certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones. The acquisition was accounted for as a business combination. See Note 3 to the audited consolidated financial statements for further information.
	On December 31, 2012, we acquired the operating assets of a nuclear and ultrasound imaging business located in the Southeastern U.S. The total purchase price was $500,000, including forgiveness of a $25,000 note receivable. Of the net purchase price, $340,000 was allocated to intangible assets and $135,000 to property, plant and equipment. The acquisition was accounted for as a business combination.
Accounting Standards Updates	Accounting Standards Updates
	In February 2013, the Financial Accounting Standards Board (FASB) issued guidance on disclosure requirements for items reclassified out of accumulated other comprehensive income. This new guidance requires entities to present (either on the face of the statement of operations or in the notes to the financial statements) the effects on the line items in the statement of operations for amounts reclassified out of accumulated other comprehensive income. We adopted this guidance beginning on January 1, 2013. The adoption did not have an effect on our financial condition or results of operations, and only resulted in a change to financial statement presentation and disclosure.
	In May 2014, the FASB issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers which supersedes most current revenue recognition guidance, including industry-specific guidance. The guidance provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. The guidance allows for either full retrospective or modified retrospective adoption and will become effective for us in the first quarter of 2017. We are currently evaluating the alternative transition methods and the potential effects of the adoption of this guidance on our financial statements.
Leases	currently lease facilities and certain automotive equipment under non-cancelable operating leases expiring from January 1, 2015 through November 30, 2021. Rent expense is recognized on a straight-line basis over the initial lease term and those renewal periods that are reasonably assured as determined at lease inception. The difference between rent expense and rent paid is recorded as deferred rent and is included in other current and long-term liabilities.
Commitments and Contingencies	Other matters. In the normal course of business, we have been, and will likely continue to be, subject to litigation or administrative proceedings incidental to our business, such as claims related to customer disputes, employment practices, wage and hour disputes, product liability, professional liability, commercial disputes, licensure restrictions or denials, and warranty or patent infringement. Responding to litigation or administrative proceedings, regardless of whether they have merit, can be expensive and disruptive to normal business operations. We are not able to predict the timing or outcome of these matters.

Basis_Of_Presentation_And_Sign2

Basis Of Presentation And Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Basis of Presentation and Significant Accounting Policies [Abstract]
Schedule of available-for-sale securities	The following table sets forth the composition of securities available-for-sale as of December 31, 2014 and 2013 (in thousands):
	As of December 31, 2014		Maturity in		Amortized Cost				Unrealized							Fair Value
			Years
									Gains				Losses
	Corporate debt securities		Less than 1 year		$	4,650			$	—			$	(5	)	$	4,645
	Corporate debt securities		1-3 years		3,304				—				(14		)	3,290
					$	7,954			$	—			$	(19	)	$	7,935
	As of December 31, 2013		Maturity in		Amortized Cost				Unrealized							Fair Value
			Years
									Gains				Losses
	Corporate debt securities		Less than 1 year		$	2,176			$	5			$	—		$	2,181
	Corporate debt securities		1-3 years		5,499				—				(7		)	5,492
					$	7,675			$	5			$	(7	)	$	7,673
	Securities available-for-sale primarily consist of investment grade corporate debt securities. We classify all securities as available-for-sale and as current assets, as the sale of such securities may be required prior to maturity to execute management strategies. These securities are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive loss in stockholders' equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. It is not more likely than not that we will be required to sell investments before recovery of their amortized costs. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and included in interest income. Interest income is recognized when earned. Realized gains and losses on investments in securities are included in other income (expense) within the consolidated statements of comprehensive income (loss). The realized gains and losses on these sales were minimal for the years ended December 31, 2014 and 2013.
Schedule of Company's allowance for doubtful accounts and billing adjustments	The following table summarizes our allowance for doubtful accounts, billing adjustments and contractual allowances as of and for the years ended December 31, 2014, 2013, and 2012 (in thousands):
			Allowance for Doubtful Accounts (1)				Reserve for Billing				Reserve for Contractual Allowances (2)
							Adjustments (2)
	Balance at December 31, 2011		$	748			$	356			$	—
	Provision adjustment		224				232				—
	Write-offs and recoveries, net		(459		)		(507		)		—
	Balance at December 31, 2012		513				81				—
	Provision adjustment		(150		)		29				—
	Write-offs and recoveries, net		(93		)		(102		)		—
	Balance at December 31, 2013		270				8				—
	Provision adjustment		571				99				18,675
	Write-offs and recoveries, net		(577		)		(100		)		(17,968		)
	Balance at December 31, 2014		$	264			$	7			$	707
	(1)	The provision was charged against general and administrative expenses.
	(2)	The provision was charged against Diagnostic Services revenue.
Schedule of excess and obsolete inventory	The following table summarizes our reserves for excess and obsolete inventory as of and for the years ended December 31, 2014, 2013, and 2012 (in thousands):
		Reserve for Excess and
		Obsolete Inventories (1)
	Balance at December 31, 2011	$	1,593
	Provision adjustment	1,164
	Write-offs and scrap	(192		)
	Balance at December 31, 2012	2,565
	Provision adjustment	210
	Write-offs and scrap	(232		)
	Balance at December 31, 2013	2,543
	Provision adjustment	(630		)
	Write-offs and scrap	—
	Balance at December 31, 2014	$	1,913
	(1)	The provision was charged against Diagnostic Imaging cost of revenues.
Schedule of Company's warranty reserve activity	The activities related to our warranty reserve for the years ended December 31, 2014, 2013, and 2012 are as follows (in thousands):
			Year Ended December 31,
			2014				2013				2012
	Balance at beginning of year		$	137			$	326			$	297
	Charges to Diagnostic Imaging cost of revenues		286				149				453
	Applied to liability		(247		)		(338		)		(424		)
	Balance at end of year		$	176			$	137			$	326
Schedule of basic and diluted net loss per share computations	The following table sets forth the computation of basic and diluted net income (loss) per share for the periods indicated (in thousands, except per share amounts):
			Year Ended December 31,
			2014				2013				2012
	Net income (loss)		$	2,475			$	264			$	(4,924	)
	Shares used to compute basic net income (loss) per share		18,571				18,789				19,274
	Dilutive potential common shares:
	Stock options		307				359				—
	Restricted stock units		—				11				—
	Shares used to compute diluted net income (loss) per share		18,878				19,159				19,274
	Basic net income (loss) per share		$	0.13			$	0.01			$	(0.26	)
	Diluted net income (loss) per share		$	0.13			$	0.01			$	(0.26	)

Supplementary_Balance_Sheet_In1

Supplementary Balance Sheet Information (Tables)	12 Months Ended
	Dec. 31, 2014
Supplementary Balance Sheet Disclosures [Abstract]
Supplemental Balance Sheet Information	Supplementary Balance Sheet Information (in thousands):
			December 31,				December 31,
			2014				2013
	Inventories:
	Raw materials		$	2,439			$	2,619
	Work-in-process		2,560				3,189
	Finished goods		558				616
	Total inventories		5,557				6,424
	Less reserve for excess and obsolete inventories		(1,913		)		(2,543		)
	Total inventories, net		$	3,644			$	3,881
			December 31,				December 31,
			2014				2013
	Property and equipment:
	Machinery and equipment		$	23,412			$	22,596
	Computer hardware and software		2,917				2,497
	Leasehold improvements		571				861
	Total property and equipment		26,900				25,954
	Less accumulated depreciation		(22,134		)		(21,801		)
	Total property and equipment, net		$	4,766			$	4,153
			December 31, 2014
			Weighted Average Useful Life (years)		Gross Carrying Amount				Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with finite useful lives:
	Customer relationships		8.6		$	4,850			$	(2,904	)	$	1,946
	Trademarks		9		600				(53		)	547
	Patents		13.2		141				(116		)	25
	Covenants not to compete		5		70				(11		)	59
	Total intangible assets, net				$	5,661			$	(3,084	)	$	2,577
			31-Dec-13
			Weighted Average Useful Life (years)		Gross Carrying Amount				Accumulated Amortization			Intangible Assets, Net (1)
	Intangible assets with finite useful lives:
	Customer relationships		5.3		$	2,940			$	(2,622	)	$	318
	Patents		12.6		141				(106		)	35
	Total intangible assets, net				$	3,081			$	(2,728	)	$	353
	-1	Amortization expense for intangible assets, net for the years ended December 31, 2014, 2013, and 2012 was $0.4 million, $0.2 million, and $0.2 million, respectively. Estimated amortization expense for intangible assets for 2015 is $0.4 million, for 2016 is $0.4 million, for 2017 is $0.4 million, for 2018 is $0.3 million, for 2019 is $0.3 million, and thereafter is $0.8 million.
			December 31,				December 31,
			2014				2013
	Other current liabilities:
	Professional fees		$	333			$	367
	Sales and property taxes payable		197				275
	Radiopharmaceuticals and consumable medical supplies		177				242
	Current portion of capital lease obligation		348				174
	Facilities and related costs		155				151
	Outside services and consulting		151				134
	Legal reserve		—				50
	Other accrued liabilities		428				381
	Total other current liabilities		$	1,789			$	1,774

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Schedule Of Fair Value Measurements
		At Fair Value as of December 31, 2014
		Level 1		Level 2		Level 3		Total
	Assets:
	Corporate debt securities	$	—	$	4,645	$	—	$	4,645
	Liabilities:
	Acquisition related contingent consideration	$	—	$	—	$	229	$	229
		At Fair Value as of December 31, 2013
		Level 1		Level 2		Level 3		Total
	Assets:
	Corporate debt securities	$	—	$	2,181	$	—	$	2,181

Commitments_And_Contingencies_1

Commitments And Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Property Subject to or Available for Operating Lease	The future minimum lease payments due under both non-cancelable operating leases and capital leases having initial or remaining lease terms in excess of one year as of December 31, 2014 are as follows (in thousands):
		Operating		Capital
		Leases		Leases
	2015	$	1,108	$	383
	2016	875		308
	2017	567		123
	2018	490		5
	2019	493		—
	Thereafter	669		—
	Total minimum lease payments	$	4,202	$	819

Share_Based_Compensation_Table

Share Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The weighted-average grant date fair value of employee stock options granted during the years ended December 31, 2014, 2013, and 2012 was $0.70, $1.06, and $1.05 per share, respectively, which was estimated using the following weighted-average assumptions:
		Year Ended December 31,
		2014		2013			2012
	Expected volatility	43	%	56	%		59	%
	Expected term (in years)	4.1		4.6			6
	Risk-free interest rate	1.2	%	0.9	%		1.2	%
	Expected dividend yield	5.7	%	—			—
Schedule of Share-based Compensation, Stock Options, Activity	A summary of our stock option award activity as of and for the year ended December 31, 2014 is as follows (in thousands, except per share data):
		Number of		Weighted-				Weighted-		Aggregate
		Shares		Average				Average		Intrinsic  Value
				Exercise				Remaining
				Price per				Contractual
				Share				Term (In Years)
	Options outstanding at December 31, 2013	856		$	1.93
	Options exercisable at December 31, 2013	501		$	1.75
	Options granted	750		$	3.38
	Options forfeited	(45	)	3.21
	Options expired	(5	)	6.98
	Options exercised	(98	)	1.92
	Options outstanding at December 31, 2014	1,458		$	2.62			5		$	2,537
	Options exercisable at December 31, 2014	553		$	1.82			3.4		$	1,403
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	A summary of our restricted stock unit activity as of and for the year ended December 31, 2014 is as follows (in thousands, except per share data):
		Number of		Weighted-
		Shares		Average
				Grant Date
				Fair Value
				Per Share
	Non-vested restricted stock units outstanding at December 31, 2013	—		$	—
	Granted	88		3.81
	Forfeited	—		—
	Vested	—		—
	Non-vested restricted stock units outstanding at December 31, 2014	88		$	—
	The following table summarizes information about restricted stock units that vested during the years ended December 31, 2014, 2013, and 2012 based on service conditions (in thousands):
		Year Ended December 31,
		2014			2013				2012
	Fair value on vesting date of vested restricted stock units	$	—		$	136			$	350
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	Allocation of Share-Based Compensation Expense
	Total share-based compensation expense related to all of our share-based units for the years ended December 31, 2014, 2013, and 2012 was allocated as follows (in thousands):
		Year Ended December 31,
	Cost of revenues:	2014			2013				2012
	Diagnostic Services	$	1		$	6			$	7
	Diagnostic Imaging	26			49				82
	Research and development	—			9				78
	Marketing and sales	51			52				127
	General and administrative	248			224				336
	Share-based compensation expense	$	326		$	340			$	630

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)
		Year Ended December 31,
		2014				2013				2012
	Current provision (benefit):
	Federal	$	—			$	(49	)		$	(128	)
	State	41				4				51
	Total current provision (benefit)	41				(45		)		(77		)
	Deferred provision:
	Federal	18				—				—
	State	3				—				—
	Total deferred provision	21				—				—
	Total income tax provision (benefit)	$	62			$	(45	)		$	(77	)
Schedule of Net Deferred Tax Assets	net deferred tax assets (liabilities) consisted of the following (in thousands):
		December 31,
		2014				2013
	Deferred tax assets (liabilities):
	Net operating loss carryforwards	$	33,732			$	34,727
	Research and development and other credits	1,950				1,928
	Reserves	1,417				1,273
	Intangibles	2,097				2,425
	Other, net	1,079				830
	Total deferred tax assets	40,275				41,183
	Deferred tax liabilities—depreciation	(237		)		(300		)
	Valuation allowance for deferred tax assets	(40,059		)		(40,883		)
	Net deferred tax assets (liabilities)	$	(21	)		$	—
Schedule of Effective Income Tax Rate Reconciliation
		Year Ended December 31,
		2014			2013			2012
	Income tax expense (benefit) at statutory federal rate	35	%		35	%		(35.0	)%
	State income tax expense (benefit), net of federal benefit	4.8	%		7.2	%		(2.9	)%
	Permanent differences and other	(2.9	)%		14.8	%		1.4	%
	Research and development credits, current year	—	%		(58.1	)%		(2.6	)%
	Research and development credits, prior year	—	%		(39.1	)%		—	%
	Change in effective state tax rates	(3.2	)%		(25.6	)%		2.4	%
	Expiration of net operating loss carryovers	1.1	%		8.2	%		36.6	%
	Stock compensation expense	0.1	%		53.7	%		—	%
	Reserve for uncertain tax positions and other reserves	—	%		5.4	%		(2.4	)%
	Change in valuation allowance	(32.5	)%		(22.2	)%		1	%
	Provision (benefit) for income taxes	2.4	%		(20.7	)%		(1.5	)%
Schedule of Unrecognized Tax Benefits Roll Forward	The following table summarizes the activity related to our unrecognized tax benefits (in thousands):
		December 31,
		2014				2013				2012
	Balance at beginning of year	$	1,553			$	1,539			$	1,621
	Increases related to prior year tax positions	—				5				25
	Increases related to current year tax positions	—				64				81
	Expiration of the statute of limitations for the assessment of taxes	—				(55		)		(252		)
	Change in valuation allowances	—				—				64
	Balance at end of year	$	1,553			$	1,553			$	1,539

Restructuring_Charges_Tables

Restructuring Charges (Tables)	12 Months Ended
	Dec. 31, 2014
Facilities Restructuring Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring and Related Costs
	(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at December 31, 2014
	Total Facilities restructuring initiative	$	—	$	663	$	660	$	3
Diagnostic Imaging Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring and Related Costs
	(in thousands)	Accrued at December 31, 2013		Accrued Costs		Cash Payments and Other Reductions		Accrued at December 31, 2014
	Total Diagnostic Imaging restructuring initiative	$	489	$	29	$	516	$	2

Segments_Tables

Segments (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment
		Year ended December 31,
		2014 (1)		2013		2012
	Gross profit by segment:
	Diagnostic Services	$	10,449	$	9,343	$	8,771
	Diagnostic Imaging	6,191		4,773		4,321
	Consolidated gross profit	$	16,640	$	14,116	$	13,092
	Income (loss) from operations by segment:
	Diagnostic Services	$	220	$	30	$	(48	)
	Diagnostic Imaging (2)	2,298		141		(5,050		)
	Consolidated income (loss) from operations	$	2,518	$	171	$	(5,098	)
	Depreciation and amortization of tangible and intangible assets by segment:
	Diagnostic Services	$	1,672	$	1,436	$	1,814
	Diagnostic Imaging	263		477		317
	Consolidated depreciation and amortization	$	1,935	$	1,913	$	2,131
		December 31,
		2014 (1)		2013
	Identifiable assets by segment:
	Diagnostic Services	$	18,724	$	11,874
	Diagnostic Imaging	23,177		29,577
	Consolidated assets	$	41,901	$	41,451
	(1) On March 13, 2014, we acquired 100% of the membership interest of Telerhythmics, LLC. The results of Telerhythmics are included in Diagnostic Services since the acquisition date (See Note 3).
	(2) Included in the Diagnostic Imaging income from operations for the year ended December 31, 2014, are approximately $0.7 million of charges associated with our Diagnostic Imaging and Facilities restructuring initiatives (See Note 11). Included in the Diagnostic Imaging income from operations for the year ended December 31, 2013, are approximately $1.7 million of charges associated with our Diagnostic Imaging restructuring initiative, as well as a gain of approximately $1.6 million associated with the sale of assets and licensing agreement from an uncommercialized surgical imaging system previously in development (See Note 12).

Quaterly_Financial_Information1

Quaterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	Summarized quarterly data for fiscal 2014 and 2013 are as follows (in thousands, except per share data):
			1st			2nd			3rd		4th
			Quarter			Quarter			Quarter		Quarter
	Fiscal 2014 (1)
	Revenues		$	12,997		$	14,587		$	13,881	$	14,143
	Gross profit		$	3,442		$	4,505		$	4,409	$	4,284
	Income (loss) from operations (2)		$	(155	)	$	825		$	1,032	$	816
	Net income (loss)		$	(148	)	$	823		$	1,028	$	772
	Net income (loss) per common share—basic (3)		$	(0.01	)	$	0.04		$	0.06	$	0.04
	Net income (loss) per common share—diluted (3)		$	(0.01	)	$	0.04		$	0.05	$	0.04
	Fiscal 2013
	Revenues		$	11,546		$	12,890		$	12,413	$	12,527
	Gross profit		$	2,817		$	3,793		$	3,818	$	3,688
	Income (loss) from operations		$	(2,409	)	$	(632	)	$	2,432	$	780
	Net income (loss)		$	(2,419	)	$	(616	)	$	2,512	$	787
	Net income (loss) per common share—basic (3)		$	(0.13	)	$	(0.03	)	$	0.14	$	0.04
	Net income (loss) per common share—diluted (3)		$	(0.13	)	$	(0.03	)	$	0.14	$	0.04
	(1)	On March 13, 2014, we acquired 100% of the membership interest of Telerhythmics, LLC. The results of Telerhythmics are included in Diagnostic Services since the acquisition date (See Note 3).
	(2)	Included in the income (loss) from operations for the first, second, third, and fourth quarter of 2014, are approximately $0.4 million, $0.1 million, $0.1 million, and less than $0.1 million of charges, respectively, associated with our Diagnostic Imaging and Facilities restructuring initiatives (See Note 11).
	(3)	Earnings per share are computed independently for each of the quarters presented. Therefore, the sum of the quarterly net earnings per share will not necessarily equal the total for the year.

Acquisition_of_Telerhythmics_T

Acquisition of Telerhythmics (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	As of December 31, 2014, the allocation of the purchase price to the assets acquired and liabilities assumed on the acquisition date was as follows (in thousands):
			Allocation of purchase price
	Assets
	Current assets:
	Accounts receivable, net		$	256
	Other current assets		34
	Total current assets		290
	Property and equipment, net		290
	Intangible assets, net		2,580
	Goodwill		1,153
	Total assets		$	4,313
	Liabilities
	Current liabilities:
	Accounts payable		$	36
	Accrued compensation		169
	Other accrued liabilities		356
	Current portion of long-term debt		131
	Total current liabilities		692
	Other liabilities		174
	Total liabilities		$	866
Business Acquisition, Pro Forma Information	The below tables display estimated pro forma results had the business acquisition been completed as of January 1, 2013. In deriving the pro forma results, we utilized the historical operating results of Telerhythmics and adjusted for the impact of the purchase accounting and transaction costs as if the acquisition occurred on January 1, 2013.
		Year Ended December 31,
		(unaudited)
	(in thousands)	2014			2013
	Revenues	$	56,763		$	55,494
	Net income	$	2,688		$	247
Condensed Income Statement	Included within our consolidated operating results for the year ended December 31, 2014 are Telerhythmics operations for the period March 14, 2014 through December 31, 2014 as follows:
	(in thousands)	Year Ended
		31-Dec-14
		(unaudited)
	Revenues	$	3,926
	Net loss	$	(777	)

The_Company_Details

The Company (Details)	12 Months Ended
	Dec. 31, 2014
	segment
The Company [Abstract]
Number of reportable segments	2

Basis_Of_Presentation_And_Sign3

Basis Of Presentation And Significant Accounting Policies - Securities Available for Sale (Details) (Corporate Debt Securities, USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost	$7,954	$7,675
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	0	5
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	-19	-7
Less than 1 year [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost	4,650	2,176
Available-for-sale Securities, Unrealized Gains	0	5
Available-for-sale Securities, Unrealized Losses	-5	0
1-3 years [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost	3,304	5,499
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax	0	0
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax	-14	-7
Level 2
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Fair Value	7,935	7,673
Level 2 | Less than 1 year [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Fair Value	4,645	2,181
Level 2 | 1-3 years [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Fair Value	$3,290	$5,492

Basis_Of_Presentation_And_Sign4

Basis Of Presentation And Significant Accounting Policies - Allowance For Doubtful Accounts (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Allowance for doubtful accounts and billing adjustments [Roll Forward]
Provision	$1,200
Allowance for Doubtful Accounts
Allowance for doubtful accounts and billing adjustments [Roll Forward]
Balance	270	[1]	513	[1]	748	[1]
Provision	571	[1]	-150	[1]	224	[1]
Write-offs and recoveries, net	-577	[1]	-93	[1]	-459	[1]
Balance	264	[1]	270	[1]	513	[1]
Reserves for Billing Adjustments and Contractual Allowances
Allowance for doubtful accounts and billing adjustments [Roll Forward]
Balance	8	[2]	81	[2]	356	[2]
Provision	99	[2]	29	[2]	232	[2]
Write-offs and recoveries, net	-100	[2]	-102	[2]	-507	[2]
Balance	7	[2]	8	[2]	81	[2]
Reserves for Contractual Allowance [Member]
Allowance for doubtful accounts and billing adjustments [Roll Forward]
Balance	0		0		0
Provision	18,675		0		0
Write-offs and recoveries, net	-17,968		0		0
Balance	$707		$0		$0
[1]	The provision was charged against general and administrative expenses.
[2]	The provision was charged against Diagnostic Services revenue.

Basis_Of_Presentation_And_Sign5

Basis Of Presentation And Significant Accounting Policies - Reserves For Excess And Obsolete Inventories (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Movement in Valuation Allowances and Reserves [Roll Forward]
Provision	$1,200
Reserve For Excess and Obsolete Inventories
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance	2,543	2,565	1,593
Provision	-630	210	1,164
Write-offs and srap	0	-232	-192
Balance	$1,913	$2,543	$2,565

Basis_Of_Presentation_And_Sign6

Basis Of Presentation And Significant Accounting Policies - Warranty (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Basis of Presentation and Significant Accounting Policies [Abstract]
Standard product warranty period	P12M
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance	$137	$326	$297
Charges to Diagnostic Imaging cost of revenues	286	149	453
Applied to liability	-247	-338	-424
Balance	$176	$137	$326

Basis_Of_Presentation_And_Sign7

Basis Of Presentation And Significant Accounting Policies - Net Income (Loss) Per Share (Details) (USD $)	3 Months Ended																	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014		Sep. 30, 2014		Jun. 30, 2014		Mar. 31, 2014		Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net Loss Per Share [Line Items]
Vested restricted stock units used to compute basic net loss per share																	44,522	5,063		221,335
Earnings Per Share, Basic and Diluted [Abstract]
Net loss	$772		$1,028		$823		($148)		$787		$2,512		($616)		($2,419)			$2,475	$264	($4,924)
Shares used to compute basic net loss per share (in dollars per share)																		18,571,000	18,789,000	19,274,000
Shares used to compute diluted net loss per share (in dollars per share)																		18,878,000	19,159,000	19,274,000
Earnings Per Share, Basic (in dollars per share)	$0.04	[1]	$0.06	[1]	$0.04	[1]	($0.01)	[1]	$0.04	[1]	$0.14	[1]	($0.03)	[1]	($0.13)	[1]		$0.13	$0.01	($0.26)
Earnings Per Share, Diluted (in dollars per share)	$0.04	[1]	$0.05	[1]	$0.04	[1]	($0.01)	[1]	$0.04		$0.14		($0.03)		($0.13)			$0.13	$0.01	($0.26)
Stock Options
Earnings Per Share, Basic and Diluted [Abstract]
Stock options																		307,000	359,000	0
Restricted Stock Units (RSUs)
Earnings Per Share, Basic and Diluted [Abstract]
Stock options																		0	11,000	0
Stock Options
Earnings Per Share, Basic and Diluted [Abstract]
Antidilutive common shares excluded from computation of diluted net loss																		66,917	177,891	268,662
Common Stock [Member]
Earnings Per Share, Basic and Diluted [Abstract]
Antidilutive common shares excluded from computation of diluted net loss																				403,670
[1]	Earnings per share are computed independently for each of the quarters presented. Therefore, the sum of the quarterly net earnings per share will not necessarily equal the total for the year.

Basis_Of_Presentation_And_Sign8

Basis Of Presentation And Significant Accounting Policies - Acquisition (Details) (USD $)	0 Months Ended
	Mar. 13, 2014	Dec. 31, 2014	Mar. 13, 2014
Business Acquisition [Line Items]
Total purchase price		$500,000
Note receivable forgiven		25,000
Intangible assets, net		340,000
Property and equipment, net		135,000
Telerhythmics [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%		100.00%
Current Liabilities, Long-term Debt	131,000	131,000	131,000
Contingent Consideration Arrangements, Range of Outcomes, Value, High	501,000		501,000
Intangible assets, net		2,580,000
Property and equipment, net		290,000
Payments to Acquire Businesses, Gross	$3,400,000

Basis_Of_Presentation_And_Sign9

Basis Of Presentation And Significant Accounting Policies (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Reserve for excess and obsolete inventory recorded	$1,200,000
Restricted cash	477,000	244,000
Shipping and handling costs	500,000	200,000	200,000
Advertising costs	$200,000	$300,000	$500,000
Machinery and Equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of the long-lived assets	6 years
Computer hardware and software
Property, Plant and Equipment [Line Items]
Estimated useful lives of the long-lived assets	3 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Estimated useful lives of the long-lived assets	5 years
Customer Relationships
Property, Plant and Equipment [Line Items]
Weighted average useful life	8 years 7 months 6 days	5 years 3 months 18 days
Trademarks
Property, Plant and Equipment [Line Items]
Weighted average useful life	9 years
Patents
Property, Plant and Equipment [Line Items]
Weighted average useful life	13 years 2 months 12 days	12 years 7 months 6 days
Noncompete Agreements
Property, Plant and Equipment [Line Items]
Weighted average useful life	5 years
Minimum [Member] | Customer Relationships
Property, Plant and Equipment [Line Items]
Weighted average useful life	5 years
Minimum [Member] | Trademarks
Property, Plant and Equipment [Line Items]
Weighted average useful life	9 years
Minimum [Member] | Patents
Property, Plant and Equipment [Line Items]
Weighted average useful life	8 years
Minimum [Member] | Noncompete Agreements
Property, Plant and Equipment [Line Items]
Weighted average useful life	5 years
Maximum [Member] | Customer Relationships
Property, Plant and Equipment [Line Items]
Weighted average useful life	9 years
Maximum [Member] | Patents
Property, Plant and Equipment [Line Items]
Weighted average useful life	15 years
Emory Healthcare [Member] | Customer Concentration Risk [Member]
Property, Plant and Equipment [Line Items]
Concentration Risk, Percentage	10.90%
Diagnostic Services [Member] | Emory Healthcare [Member] | Customer Concentration Risk [Member]
Property, Plant and Equipment [Line Items]
Concentration Risk, Percentage	14.30%

Supplementary_Balance_Sheet_In2

Supplementary Balance Sheet Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Inventory, Net [Abstract]
Raw materials	$2,439,000	$2,619,000
Work-in-process	2,560,000	3,189,000
Finished goods	558,000	616,000
Total inventories	5,557,000	6,424,000
Less reserve for excess and obsolete inventories	-1,913,000	-2,543,000
Total inventories, net	3,644,000	3,881,000
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	26,900,000	25,954,000
Less accumulated depreciation	-22,134,000	-21,801,000
Total property and equipment, net	4,766,000	4,153,000
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Intangible assets, gross	5,661,000	3,081,000
Accumulated amortization	-3,084,000	-2,728,000
Finite-Lived Intangible Assets, Net	2,577,000	353,000
Amortization of intangible assets	356,000	231,000	233,000
2015	400,000
2016	400,000
2017	400,000
2018	300,000
2019	300,000
Accrued Liabilities, Current [Abstract]
Professional fees	333,000	367,000
Sales and property taxes payable	197,000	275,000
Radiopharmaceuticals and consumable medical supplies	177,000	242,000
Current portion of capital lease obligation	348,000	174,000
Facilities and related costs	155,000	151,000
Outside services and consulting	151,000	134,000
Legal reserve	0	50,000
Other accrued liabilities	428,000	381,000
Total other current liabilities	1,789,000	1,774,000
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	800,000
Leasehold Improvements
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	571,000	861,000
Computer hardware and software
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	2,917,000	2,497,000
Machinery and Equipment
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	23,412,000	22,596,000
Customer Relationships
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Weighted average useful life	8 years 7 months 6 days	5 years 3 months 18 days
Intangible assets, gross	4,850,000	2,940,000
Accumulated amortization	-2,904,000	-2,622,000
Finite-Lived Intangible Assets, Net	1,946,000	318,000
Trademarks
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Weighted average useful life	9 years
Intangible assets, gross	600,000
Accumulated amortization	-53,000
Finite-Lived Intangible Assets, Net	547,000
Noncompete Agreements
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Weighted average useful life	5 years
Intangible assets, gross	70,000
Accumulated amortization	-11,000
Finite-Lived Intangible Assets, Net	59,000
Patents
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Weighted average useful life	13 years 2 months 12 days	12 years 7 months 6 days
Intangible assets, gross	141,000	141,000
Accumulated amortization	-116,000	-106,000
Finite-Lived Intangible Assets, Net	$25,000	$35,000

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Mar. 13, 2014	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$220,000
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure		0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure		0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure		229,000
Corporate Debt Securities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Company's assets recorded at fair value		0	0
Corporate Debt Securities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Company's assets recorded at fair value		7,935,000	7,673,000
Corporate Debt Securities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Company's assets recorded at fair value		0	0
Telerhythmics [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Arrangements, Range of Outcomes, Value, High	501,000
Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial and Nonfinancial Liabilities, Fair Value Disclosure		229,000
Total | Corporate Debt Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Company's assets recorded at fair value		$4,645,000	$2,181,000

Goodwill_Details

Goodwill (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2008	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment loss	$2,500,000	$0	$0	$0
Goodwill		1,337,000	184,000
Goodwill, Acquired During Period		$1,200,000

Commitments_And_Contingencies_2

Commitments And Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Operating lease rent expense	$1,300,000	$1,400,000
Operating Leases
2015	1,108,000
2016	875,000
2017	567,000
2018	490,000
2019	493,000
Thereafter	669,000
Total minimum lease payments	4,202,000
Capital Leases
2015	383,000
2016	308,000
2017	123,000
2018	5,000
2019	0
Thereafter	0
Total minimum lease payments	$819,000

Commitments_And_Contingencies_3

Commitments And Contingencies Loss Contingency, Settlement Agreement, Consideration (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]
Loss Contingency, Settlement Agreement, Consideration	$385

Share_Based_Compensation_Narra

Share Based Compensation - Narrative (Details) (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Aggregate number of shares of common stock authorized to issue under the Plans (shares)	1,856,733
Shares available for future issuance under the Plans (shares)	1,131,432
Number of shares reserved for issuance under the Plans	1,500
Stock Options
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock options contractual term under the Plans	5 years
Weighted average grabnt-date fair value of options granted	$0.70	$1.06	$1.05
Unrecognized compensation cost	$0.50
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 9 months 18 days
Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options	0.2	0.9	0.3
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value	$0.10	$0.90	$0.10
Stock Options | Minimum [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock options requisite service period under the Plans	2 years
Stock options contractual term under the Plans	7 years
Stock Options | Maximum [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock options requisite service period under the Plans	4 years
Stock options contractual term under the Plans	10 years
Restricted Stock
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Restricted stock settlement period under the Plans	36 months
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 6 months
Weighted average grant-date fair value of the restricted stock units	$3.81		$1.82
Restricted Stock | Minimum [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
restricted stock vesting period under the Plans	1 year
Restricted Stock | Maximum [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
restricted stock vesting period under the Plans	3 years

Share_Based_Compensation_Stock

Share Based Compensation - Stock Options Fair Value Weighted Average Valuation Assumptions (Details) (Stock Options)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	43.00%	56.00%	59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	4 years 1 month 6 days	4 years 7 months 6 days	6 years
Expected term (in years)	P4Y1M6D	P4Y7M6D	P6Y
Risk-free interest rate	1.20%	0.90%	1.20%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	5.70%	0.00%	0.00%

Share_Based_Compensation_Stock1

Share Based Compensation - Stock Options Activity (Details) (Stock Options, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	5.70%	0.00%	0.00%
Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options	$200,000	$900,000	$300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Total Intrinsic Value	100,000	900,000	100,000
Number of Shares [Roll Forward]
Options outstanding at December 31, 2011 (shares)	856
Options exercisable at December 31, 2011 (shares)	501
Options granted (shares)	750
Options forfeited (shares)	-45
Options expired (shares)	-5
Options exercised (shares)	-98
Options outstanding at December 31, 2012 (shares)	1,458	856
Options exercisable at December 31, 2012 (shares)	553	501
Weighted Average Exercise Price per Share [Roll Forward]
Options outstanding at December 31, 2011 - Weighted Average Exercise Price per Share (US$ per share)	$1.93
Options exercisable at December 31, 2011 - Weighted Average Exercise Price per Share (US$ per share)	$1.75
Options granted - Weighted Average Exercise Price per Share (US$ pre share)	$3.38
Options forfeited - Weighted Average Exercise Price per Share (US$ per share)	$3.21
Options expired - Weighted Average Exercise Price per Share (US$ per share)	$6.98
Options exercised - Weighted Average Exercise Price per Share (US$ per share)	$1.92
Options outstanding at December 31, 2012 - Weighted Average Exercise Price per Share (US$ per share)	$2.62	$1.93
Options exercisable at December 31, 2012 - Weighted Average Exercise Price per Share (US$ per share)	$1.82	$1.75
Options outstanding - Weighted Average Remaining Contractual Term (in years)	5 years
Options exercisable - Weighted Average Remaining Contractual Term (in years)	3 years 4 months 12 days
Options outstanding at December 31, 2012 - Aggregate Intrinsic Value	2,537,000
Options exercisable at December 31, 2012 - Aggregate Intrinsic Value	$1,403,000

Share_Based_Compensation_Restr

Share Based Compensation - Restricted Stock Activity (Details) (Restricted Stock, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$300,000
Nonvested Resticted Stock Units - Number of Shares [Roll Forward]
Non-vested restricted stock units outstanding at December 31, 2011 (shares)	88	0
Granted (shares)	88
Forfeited (shares)	0
Vested (shares)	0
Non-vested restricted stock units outstanding at December 31, 2011 (shares)	88	0
Nonvested Restricted Stock Units - Weighted Average Grant Date Fair Value [Roll Forward]
Non-vested restricted stock units outstanding at December 31, 2011 - Weighted Average Grant Date Fair Value	$0
Granted (US$ per share)	$3.81		$1.82
Forfeited (US$ per share)	$0
Vested (US$ per share)	$0
Non-vested restricted stock units outstanding at December 31, 2011 - Weighted Average Grant Date Fair Value	$0	$0
Fair value on vesting date of vested restricted stock units	$0	$136,000	$350,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 6 months

Share_Based_Compensation_Alloc

Share Based Compensation - Allocation of Share-based Compensation Expense (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$326	$340	$630
DIS
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1	6	7
Diagnostic Imaging
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	26	49	82
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	0	9	78
Marketing and sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	51	52	127
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$248	$224	$336

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating Loss Carryforwards [Line Items]
State income tax net operating loss carryforwards	$28,000,000
Unrecognized Tax Benefits - Balance at end of year	1,553,000	1,553,000	1,539,000	1,621,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	1,300,000
Internal Revenue Service (IRS)
Operating Loss Carryforwards [Line Items]
Federal income tax net operating loss carryforwards	93,200,000
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Federal and California research and other credit carryforwards	1,800,000
Federal And California Tax Authority
Operating Loss Carryforwards [Line Items]
Federal and California research and other credit carryforwards	2,100,000
Expiring In Year Two | State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
State loss carryforward subject to expiration	$4,100,000

Income_Taxes_Income_Tax_Provis

Income Taxes - Income Tax Provision (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Current Federal Tax Expense (Benefit)	$0	($49)	($128)
Current State and Local Tax Expense (Benefit)	41	4	51
Current Income Tax Expense (Benefit)	41	-45	-77
Deferred Federal Income Tax Expense (Benefit)	18	0	0
Deferred State and Local Income Tax Expense (Benefit)	3	0	0
Deferred Income Tax Expense (Benefit)	21	0	0
Income Tax Expense (Benefit)	$62	($45)	($77)

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Effective Income Tax Rate Reconciliation Line Items [Abstract]
Income tax expense (benefit) at statutory federal rate	35.00%	35.00%	-35.00%
State income tax expense (benefit), net of federal benefit	4.80%	7.20%	-2.90%
Permanent differences and other	-2.90%	14.80%	1.40%
Research and development credits, current year	0.00%	-58.10%	-2.60%
Research and development credits, prior year	0.00%	-39.10%	0.00%
Change in effective state tax rates	-3.20%	-25.60%	2.40%
Expiration of net operating loss carryovers	1.10%	8.20%	36.60%
Stock compensation expense	0.10%	53.70%	0.00%
Reserve for uncertain tax positions and other reserves	0.00%	5.40%	-2.40%
Change in valuation allowance	-32.50%	-22.20%	1.00%
Provision (benefit) for income taxes	2.40%	-20.70%	-1.50%

Income_Taxes_Net_Deferred_Tax_

Income Taxes - Net Deferred Tax Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$33,732	$34,727
Research and development and other credits	1,950	1,928
Reserves	1,417	1,273
Intangibles	2,097	2,425
Other, net	1,079	830
Total deferred tax assets	40,275	41,183
Deferred tax liabilities—depreciation	-237	-300
Valuation allowance for deferred tax assets	-40,059	-40,883
Net deferred tax assets (liabilities)	($21)	$0

Income_Taxes_Unrecognized_Tax_

Income Taxes - Unrecognized Tax Benefit Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$1,300,000
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized Tax Benefits - Balance at beginning of year	1,553,000	1,539,000	1,621,000
Change in valuation amount	0	0	64,000
Expiration of the statute of limitations for the assessment of taxes	0	-55,000	-252,000
Increases related to current year tax positions	0	64,000	81,000
Increases related to prior year tax positions	0	5,000	25,000
Unrecognized Tax Benefits - Balance at end of year	$1,553,000	$1,553,000	$1,539,000

Employee_Retirement_Plan_Detai

Employee Retirement Plan (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]
Maximum annual contribution of annual salary per employee	100.00%
The Company's contributions to its retirement plans	$0.20	$0.20

Restructuring_Charges_Diagnost

Restructuring Charges - Diagnostic Imaging Restructuring Initiative (Details) (USD $)	3 Months Ended			12 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$100,000	$100,000	$400,000	$692,000	$1,728,000	$0
Diagnostic Imaging Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve				2,000	489,000
Restructuring and Related Cost, Incurred Cost				1,800,000
Restructuring charges				29,000
Payments for Restructuring				516,000
Diagnostic Imaging Initiative [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Incurred Cost				$1,600,000

Restructuring_Charges_Faciliti

Restructuring Charges - Facilities Restructuring Initiative (Details) (USD $)	3 Months Ended			12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 27, 2014	Jan. 23, 2014
							sqft	sqft
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$100	$100	$400	$692	$1,728	$0
Facilities Restructuring Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve				3	0
Restructuring charges				663
Payments for Restructuring				$660
Approximate square footage of manufacturing and office space							47,000	21,300

Surgical_Imaging_Asset_Sale_an1

Surgical Imaging Asset Sale and License Agreement (Details) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of assets and license agreement	$0	($1,568,000)	$0
Novadaq Technologies [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Sale of Machinery and Equipment				2,000,000
Regulatory And Commercial Milestones [Member] | Novadaq Technologies [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Deferred Contingent Payments, Maximum Consideration That Can Be Received				$1,000,000

Stock_Repurchase_Program_Detai

Stock Repurchase Program (Details) (2009 Stock Repurchase Program [Member], USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Mar. 13, 2013	Feb. 27, 2013
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Authorized Amount				$12	$7
Stock Repurchase Program, Remaining Authorized Repurchase Amount			$6.30
Common Stock [Member]
Equity, Class of Treasury Stock [Line Items]
Stock Repurchased During Period, Shares	1,514,843	490,816

Preferred_Stock_Rights_Narrati

Preferred Stock Rights (Narrative) (Details) (USD $)	0 Months Ended
	Jun. 04, 2013	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Common Stock, Par value (usd per share)	0.0001	$0.00	$0.00
Preferred Stock, Par value (usd per share)		$0.00	$0.00
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Par value (usd per share)	0.0001
Exercise Price of Warrants (usd per share)	20
Common Stock [Member]
Class of Stock [Line Items]
Common Stock ownership percentage	4.99%

Segments_Details

Segments (Details) (USD $)	3 Months Ended												12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Sep. 30, 2014		Jun. 30, 2014		Mar. 31, 2014		Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Segment Reporting Information [Line Items]
Consolidated gross profit	$4,284		$4,409		$4,505		$3,442		$3,688	$3,818	$3,793	$2,817	$16,640		$14,116		$13,092
Consolidated loss from operations	816	[1]	1,032	[1]	825	[1]	-155	[1]	780	2,432	-632	-2,409	2,518		171		-5,098
Consolidated depreciation and amortization													1,935		1,913		2,131
Consolidated assets	41,901								41,451				41,901		41,451
Restructuring charges			100		100		400						692		1,728		0
Gain on sale of assets and license agreement													0		1,568		0
DIS
Segment Reporting Information [Line Items]
Consolidated gross profit													10,449		9,343		8,771
Consolidated loss from operations													220		30		-48
Consolidated depreciation and amortization													1,672		1,436		1,814
Consolidated assets	18,724								11,874				18,724		11,874
Diagnostic Imaging
Segment Reporting Information [Line Items]
Consolidated gross profit													6,191		4,773		4,321
Consolidated loss from operations													2,298	[2]	141	[2]	-5,050	[2]
Consolidated depreciation and amortization													263		477		317
Consolidated assets	$23,177								$29,577				$23,177		$29,577
[1]	(1) On March 13, 2014, we acquired 100% of the membership interest of Telerhythmics, LLC. The results of Telerhythmics are included in Diagnostic Services since the acquisition date (See Note 3).(2) Included in the income (loss) from operations for the first, second, third, and fourth quarter of 2014, are approximately $0.4 million, $0.1 million, $0.1 million, and less than $0.1 million of charges, respectively, associated with our Diagnostic Imaging and Facilities restructuring initiatives (See Note 11).
[2]	Included in the Diagnostic Imaging income from operations for the year ended December 31, 2014, are approximately $0.7 million of charges associated with our Diagnostic Imaging and Facilities restructuring initiatives (See Note 11). Included in the Diagnostic Imaging income from operations for the year ended December 31, 2013, are approximately $1.7 million of charges associated with our Diagnostic Imaging restructuring initiative, as well as a gain of approximately $1.6 million associated with the sale of assets and licensing agreement from an uncommercialized surgical imaging system previously in development (See Note 12).

Quaterly_Financial_Information2

Quaterly Financial Information (Unaudited) (Details) (USD $)	3 Months Ended																12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014		Sep. 30, 2014		Jun. 30, 2014		Mar. 31, 2014		Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Restructuring charges			$100		$100		$400										$692	$1,728	$0
Revenue	14,143		13,881		14,587		12,997		12,527		12,413		12,890		11,546		42,170	37,171	36,064
Gross profit	4,284		4,409		4,505		3,442		3,688		3,818		3,793		2,817		16,640	14,116	13,092
Loss from operations	816	[1]	1,032	[1]	825	[1]	-155	[1]	780		2,432		-632		-2,409		2,518	171	-5,098
Net income (loss)	772		1,028		823		-148		787		2,512		-616		-2,419		2,475	264	-4,924
Earnings Per Share, Basic (in dollars per share)	$0.04	[2]	$0.06	[2]	$0.04	[2]	($0.01)	[2]	$0.04	[2]	$0.14	[2]	($0.03)	[2]	($0.13)	[2]	$0.13	$0.01	($0.26)
Earnings Per Share, Diluted (in dollars per share)	$0.04	[2]	$0.05	[2]	$0.04	[2]	($0.01)	[2]	$0.04		$0.14		($0.03)		($0.13)		$0.13	$0.01	($0.26)
Gain on sale of assets and license agreement																	$0	($1,568)	$0
[1]	(1) On March 13, 2014, we acquired 100% of the membership interest of Telerhythmics, LLC. The results of Telerhythmics are included in Diagnostic Services since the acquisition date (See Note 3).(2) Included in the income (loss) from operations for the first, second, third, and fourth quarter of 2014, are approximately $0.4 million, $0.1 million, $0.1 million, and less than $0.1 million of charges, respectively, associated with our Diagnostic Imaging and Facilities restructuring initiatives (See Note 11).
[2]	Earnings per share are computed independently for each of the quarters presented. Therefore, the sum of the quarterly net earnings per share will not necessarily equal the total for the year.

Subsequent_Event_Dividend_Paya

Subsequent Event - Dividend Payable (Details) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 02, 2015
Subsequent Event [Line Items]
Common stock dividends declared (usd per share)	$0.20	$0.05	$0
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock dividends declared (usd per share)				$0.05

Subsequent_Event_MD_Office_Acq

Subsequent Event MD Office Acquisition (Details) (Subsequent Event [Member], USD $)	0 Months Ended
	Mar. 05, 2015	Mar. 05, 2015
MD Office [Member]
Subsequent Event [Line Items]
Payments to Acquire Businesses, Gross	$2,684,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	610,000
Contingent Consideration Arrangements, Range of Outcomes, Value, High	400,000	400,000
Percentage Of EBITDA To Be Received	50.00%
Year one to Year three [Member]
Subsequent Event [Line Items]
Contingent Consideration Arrangements, Range of Outcomes, Value, High	$650,000	$650,000

Acquisition_of_Telerhythmics_D

Acquisition of Telerhythmics (Details) (USD $)	3 Months Ended								12 Months Ended			0 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 13, 2014
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Property and equipment, net	$135,000								$135,000
Intangible assets, net	340,000								340,000
Net income (loss)	772,000	1,028,000	823,000	-148,000	787,000	2,512,000	-616,000	-2,419,000	2,475,000	264,000	-4,924,000
Telerhythmics [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired												100.00%
Payments to Acquire Businesses, Gross												3,400,000
Current Liabilities, Long-term Debt	131,000								131,000			131,000
Contingent Consideration Arrangements, Range of Outcomes, Value, High												501,000
Percentage Of EBITDA To Be Received												50.00%
Contingent Consideration, Liability												229,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]
Accounts receivable, net	256,000								256,000
Other current assets	34,000								34,000
Total current assets	290,000								290,000
Property and equipment, net	290,000								290,000
Intangible assets, net	2,580,000								2,580,000
Goodwill	1,153,000								1,153,000
Total assets	4,313,000								4,313,000
Accounts payable	36,000								36,000
Accrued compensation	169,000								169,000
Other accrued liabilities	356,000								356,000
Total current liabilities	692,000								692,000
Other liabilities	174,000								174,000
Total liabilities	866,000								866,000
Revenues									56,763,000	55,494,000
Net income									2,688,000	247,000
Revenues									3,926,000
Net income (loss)									-777,000
Business Acquisition, Transaction Costs	155,000								155,000
Year one [Member] | Telerhythmics [Member]
Business Acquisition [Line Items]
Contingent Consideration Arrangements, Range of Outcomes, Value, High												415,000
Year two [Member] | Telerhythmics [Member]
Business Acquisition [Line Items]
Contingent Consideration Arrangements, Range of Outcomes, Value, High												825,000
Year three [Member] | Telerhythmics [Member]
Business Acquisition [Line Items]
Contingent Consideration Arrangements, Range of Outcomes, Value, High												$825,000